



### Moderating Effects of Exercise Duration and Intensity in Neuromuscular vs. Endurance Exercise Interventions for the Treatment of Depression: A Meta-Analytical Review

Exercise Training German Sport University Cologne, Köln, Germany

Lukas Nebiker<sup>1</sup>, Eric Lichtenstein<sup>1</sup>, Alice Minghetti<sup>1</sup>, Lukas Zahner<sup>1</sup>, Markus Gerber<sup>1</sup>, Oliver Faude<sup>1</sup> and Lars Donath<sup>2\*</sup>

OPEN ACCESS

#### Edited by:

Michele Fornaro, Columbia University, New York State Psychiatric Institute, United States

#### Reviewed by:

Stefano Novello, Università degli Studi di Napoli Federico II, Italy Andrea Fusco, Università degli Studi di Napoli Federico II, Italy

\*Correspondence:

I.donath@dshs-koeln.de

#### Specialty section:

This article was submitted to Mood and Anxiety Disorders, a section of the journal Frontiers in Psychiatry

> **Received:** 08 May 2018 **Accepted:** 19 June 2018 **Published:** 19 July 2018

#### Citation:

Nebiker L, Lichtenstein E, Minghetti A, Zahner L, Gerber M, Faude O and Donath L (2018) Moderating Effects of Exercise Duration and Intensity in Neuromuscular vs. Endurance Exercise Interventions for the Treatment of Depression: A Meta-Analytical Review. Front. Psychiatry 9:305. doi: 10.3389/fpsyt.2018.00305 **Background:** Exercise training is a beneficial treatment strategy for depression. Previous meta-analytical reviews mainly examined the effect of aerobic exercise on depressive symptoms neglecting comparisons with neuromuscular training and meta-regression considering relevant exercise training prescriptors such as exercise duration, intensity, number of exercise sessions (volume) and frequency.

<sup>1</sup> Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland, <sup>2</sup> Department of Intervention Research in

**Methods:** A structured literature search was conducted in biomedical and psychological databases and study selection was conducted following the PICOS approach. (Randomized) controlled trials that compared supervised neuromuscular or endurance exercise interventions with an inactive control group (CON) in clinically depressed in- or out-patients over 18 years were included. Eligibility and study quality were evaluated by two independent researchers. Standardized mean differences (SMD) for the reduction of depressive symptoms, measured with different evaluation scales (e.g., BDI, HAM-D, PHQ-9, HRSD, MADRS, GDS) were calculated with the adjusted Hedges'g equation as main outcome for the comparison of endurance and neuromuscular exercise interventions vs. CON. Statistical analyses were conducted using a random effects inverse-variance model. Multivariate meta-regression analysis was performed in order to examine the modulating effects of exercise training prescriptors.

**Results:** Twenty seven trials with 1,452 clinically depressed adults were included. 20 out of 27 included trials reached a PEDro score of at least 6, representing high-quality. Irrespective of the exercise mode and study quality, large effects in favor of exercise compared to the control condition were found. Compared to CON, sensitivity analyses revealed a moderate to large effect in favor of endurance exercise [SMD: -0.79 (90% Cl: -1.10, -0.48); p < 0.00001,  $l^2 = 84\%$ ] and a large effect size in favor of neuromuscular exercise [SMD: -1.14 (90 Cl: -1.50, -0.78); p < 0.00001,  $l^2 = 80\%$ ]. These effects decreased

1

to moderate for endurance and remained large for neuromuscular trials when considering studies of high quality, indicating a significant difference (p = 0.04). Multivariate meta- regression revealed that exercise duration in endurance trials and exercise intensity in neuromuscular trials had a significantly moderating effect.

**Conclusions:** Strong neuromuscular exercise interventions can be slightly more effective than endurance exercise interventions. Interestingly, exercise duration and exercise intensity moderated the effect size meaningfully. This result might be used on exercise in depression to increase efficacy.

Keywords: endurance, exercise, duration, intensity, major depressive disorder, RCT, strength, training

### INTRODUCTION

Depression is considered a leading cause of disability worldwide and a major contributor to the overall global burden of disease (1). According to the WHO (1), several effective treatments for depression exist but less than half of the affected people receive such treatments. According to Ebmeier et al. (2) and Halliwell et al. (3), merely 18–25% of the depressed patients receive an adequate treatment with antidepressant medication and psychotherapy.

Moreover, the treatment with antidepressant medication is accompanied with poor compliance (4) and has been reported to cause several unintended side effects like withdrawal symptom (2), nausea, insomnia, anxiety (5), weight gain (6), or sexual dysfunction (7). Therefore, further evidence-based alternative or complementary treatment approaches for depressive disorders are needed.

The WHO (8) and the NICE (9) guidelines recommend physical exercise as a standard complementary treatment option for depression. Exercise as a complementary treatment option provides various benefits such as decreased blood pressure (10), weight reduction (11), increased oxygen uptake (12, 13) while negligible side effects are known (11).

The beneficial effect of physical exercise in the treatment of depression has previously been examined in several metaanalyses. Due to a large heterogeneity of included studies in terms of study quality, diagnosis of depression, mode of exercise, included subjects and duration, the effect sizes given as standardized mean difference (SMD) range between small effects in favor of exercise [-0.34 (14) to -0.40 (15)], moderate effects [-0.77 (16) to -0.72 (17)] or significant large effects [-0.80 (10),-0.82 (18), -1.1 (19), -1.1 (20), and -1.39 (21)]. Interestingly, meta-analyses that included only methodological strong trials revealed lower effect sizes. For instance, Krogh et al. (22) and Mead et al. (18) reported SMDs of -0.19 and -0.42, respectively. Another example is the meta-analysis of Lawlor and Hopker (19), which resulted in an effect size of -0.69 after removing 41% of all studies due to poor methodological quality (23).

Even though the antidepressant effects of exercise for the treatment of depression are well-understood, the moderating effect of training prescriptors (e.g., exercise frequency, intensity, duration of sessions, number of sessions) and the difference between neuromuscular vs. endurance training remains elusive

to date. A differentiation between neuromuscular and endurance exercise seems beneficial as patients do have different exercise preferences and both exercise modes cause different adaptations on behavioral and molecular level (24). Against this background, the purpose of the present systematic review and metaanalysis with meta-regression is to (a) update the effects of physical exercise in the treatment of depression following precise inclusion criteria and sound methodological quality, (2) examine the effects of endurance exercise interventions and neuromuscular exercise interventions on depression, and (3) execute a meta-regression analyses including the different training parameters, which could influence the effect sizes of exercise on depression.

### **METHODS**

#### Search Strategy


The present meta-analysis was performed along the PRISMA guidelines (25). Biomedical and psychological databases (PubMed, SPORTDiscus, CINAHL, Cochrane Library, ProQuest Database) were screened from the 17th of February to the 28th of November 2017. Similar key words and Boolean conjunctions (OR/AND) were used as in the meta-analysis of Schuch et al. (26): [(exercis\* OR aerobic\* OR running\* OR jogging\* OR walk\* OR hiking OR swim\* OR aquatic\* OR cycling OR bicycl\* OR strength\* OR flexibility AND activit\* OR fitness OR train\* OR "physical medicine" OR resistance OR lift\*) AND [depress\* OR dysthymia]].

In addition, recent reviews and cited articles about exercise and depression were screened and potentially eligible articles were added to the library. Duplicates were identified and excluded. The remaining studies were gradually screened using the titles, abstracts and full-texts of the potentially eligible articles (**Figure 1**). The final decision for inclusion or exclusion was made by two independent authors (LN, LD) based on the inclusion criteria.

### **Inclusion Criteria**

Eligible studies had to meet the following inclusion criteria based on the PICOS approach (27) for population (P), intervention (I), comparators (C), main outcome (O), and study design (S):

-(P) Participants had to be  $\geq$  18 years of age and were either diagnosed using the Diagnostic and Statistical Manual of



Mental Disorders, Fourth Edition (DSM-IV) criteria for MDD, a diagnosis of MDD with the International Classification of Diseases (ICD-10), 10th revision, a diagnosis of MDD using the Research Diagnostic criteria (RDC), a diagnosis for depression using the Structured Clinical Interview for Depression (SCID), the 21-item Beck Depression Inventory II (BDI-II), the Geriatric Depression Scale (GDS), or the 9-item Patient Health Questionnaire (PHQ-9).

- -(I) The (randomized) controlled trials should investigate exercise in the sense that improvement or maintenance of at least one component of physical fitness was the objective. Physical exercise sessions had to be supervised by coaches, medical students or similar experts. The exercise interventions could either be aerobic exercises, strength exercises, functional exercise training, yoga or tai chi. The participants completed at least 10 physical exercise sessions.
- -(C) There must be a control group (CON), which did not follow a physical exercise intervention like aerobic exercise, strength exercise, yoga exercise, stretching, or relaxation exercise. The control group can either be a control group with behavioral therapy, light therapy, medication therapy, a placebo-group, or an inactive control group.

- -(O) At least one outcome for the depression score had to be evaluated in the study. That could either be the Beck Depression Score (BDI) or BDI-II, Hamilton Rating Scale for Depression (HAM-D, HRSD, HDRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Center for Epidemiological Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), or the 9-item Patient Health Questionnaire (PHQ-9). Depressive symptoms must be measured or reported pre- and post-intervention.
- -(S) Studies had to be (randomized) controlled interventions with pre- and post-testing and an intervention duration of at least 10 days and 10 sessions, respectively.

### **Exclusion Criteria**

Studies were excluded when they met one of the following criteria: (1) children or adolescents < 18 years old. (2) Participants without a diagnosis of depression. (3) Participants with chronic illnesses or further diseases apart from MDD (e.g., diabetes). (4) Inappropriate physical exercise interventions or interventions without physical exercise (e.g., mindfulness-based stress reduction therapy). (5) Exercise interventions with non-supervised sessions. (6) Invalid target outcomes (see inclusion criteria). (6) No adequate control condition or control group.

## Assessment of Methodological Quality of the Studies

The methodological quality of all eligible trials was assessed using the PEDro (Physiotherapy Evidence Database) scale. The PEDro scale contains 11 dichotomous (yes or no) items, in which the criteria 2–9 rate randomization and internal validity and the criteria 10–11 rate the presence of statistical replicable results. Criterion 1 relates to the external validity but will not be used to calculate the PEDro score.

Studies were rated independently by two non-blinded reviewers (LN and EL) and they needed to obtain consensus on every item. Discordant study ratings were discussed point to point by the two reviewers (LN and EL) to come to a decision. To represent a high-quality study, the PEDro score had to be  $\geq 6$  on the scale from 0 to 10.

### Outcome

The intervention was the mean change in depressive symptoms from baseline to post-intervention measures in the exercise groups compared to the control groups. Stratification to sex, medication and severity was not doable due to the small resulting subgrouping and overall power of the calculations. The standardized outcome was calculated as the standardized mean differences (SMD) and presented as means together with 90% confidence intervals (CI). If included studies contain more than one outcome measure meeting our criteria (mean change pre-and post in depressive symptoms), we prioritized the common scales BDI/BDI-II or HAMD to further minimize heterogeneity of our findings [e.g., (28)]. In studies reporting more than one exercise group (differing in exercise intensity or type of exercise), all exercise groups were included in the meta-analysis and allocated either to endurance exercise intervention or neuromuscular exercise intervention [e.g., (29)]. The latter category included

traditional strength or resistance training as well as Yoga or Tai-Chi based exercise regimen. Those approaches were initially analyzed independently and further pooled to "neuromuscular training" once they did not reveal significantly different effect sizes.

### **Data Extraction and Categorization**

The following data were extracted by two researchers (LN and EL) and transferred to an excel spread sheet: sample (number of participants in the intervention group and in the control group), exercise (type of exercise, number of sessions, duration of one session, weekly frequency, intensity of the sessions), outcome [pre- and post-test means and standard deviations (SD)]. Exercise intensity was described in the studies in several ways. For the sake of comparability, the different measured values (i.e., maximum oxygen uptake, heart rate reserve or Borg Scale) were categorized in the following intensity groups to make the comparison of underlying exercise intensities more suitable: low intensity (40% of maximal heart rate), low to moderate intensity (50%), moderate intensity (60%), moderate to high intensity (70%), and high intensity (80%). The exercise intensity in trials with Tai Chi or Yoga exercise interventions was not described thus we assumed low to moderate intensity.

Further relevant study information concerning reference (author and date of publication), study- design, number of participants, mean age, interventional characteristics (experimental and control group) as well as training characteristics and outcome measures were additionally described in **Table 1** (study overview for neuromuscular exercise interventions) and **Table 2** (study overview for endurance exercise interventions). All intervention trials that focused on aerobic or endurance exercise with a more pronounced cardiovascular stimulus were categorized as "endurance" and all exercise that entail coordination exercises or strength elements were categorized as "neuromuscular."

### **Statistical Analysis and Bias Assessment**

The SMDs (with 90% CIs) of the outcome were calculated as a measure of the effectiveness of the treatment and could be either positive or negative. We used the adjusted Hedges' g equation (Equation 1) where  $m_{1i}$  is the post- treatment mean of the intervention group and  $m_{2i}$  is the post- treatment mean of the control group, divided through the pooled standard deviation  $s_i$ . The adjusted Hedges' g equation was used to take small sample biases into account.

The Cochrane Review Manager Software (Version 5.3) was used to calculate the inverse-variance method according to Deeks and Higgins (55), using the random effects model (56). Several forest plots were generated for the outcome categories general exercise interventions, endurance interventions and neuromuscular interventions. The comparing of weaker (<6 PEDro scale) and stronger ( $\geq 6$  of PEDro scale) studies was performed in a sensitivity analyses for the risk of bias assessment. To examine a potential publication bias, a funnel plot evaluation was performed.

Based on the recommendations of Cohen (57), the value of SMD was classified according to the following scale: 0-0.19

indicates negligible effect, 0.20–0.49 indicates small effect, 0.50–0.79 indicates moderate effect and  $\geq$ 0.80 indicates large effect.

Further, we conducted a multivariate meta-regression analysis to examine the effects of the moderator variables on the study effect sizes. Our potential moderator variables were number of exercise sessions, frequency of exercise sessions, exercise intensity or exercise session duration.

$$SMD_i = \frac{m_{1i} - m_{2i}}{s_i} \left(1 - \frac{3}{4N_i - 9}\right)$$

### RESULTS

### **Trial Flow**

We identified 10,831 articles as potentially relevant throughout the search procedure (**Figure 1**, flow chart). After removing duplicates, the remaining 7,012 articles were screened for irrelevant titles. During this step, 5,237 irrelevant titles were removed and the abstracts of the remaining 1,775 potentially relevant articles were studied. One hundred abstracts did fulfill the inclusion criteria and those 100 full-texts were thoroughly studied for eligibility. Another 73 articles did not meet inclusion criteria due to several reasons (e.g., no exercise intervention, no adequate control group, no MDD- diagnosis, exercise intervention was not supervised, participants with further chronic diseases in addition to depressive disorder included, invalid target outcome, etc.). Finally, 27 intervention trials were included in this meta-analytical review.

### **Study Characteristics and Participants**

Across the 27 included studies, 17 intervention trials comprised two study arms with an endurance intervention and with a control condition and 10 intervention trials comprised two study arms with neuromuscular interventions and control conditions. In total, 1'452 depressed participants out of the included 27 trials were used for our meta-analysis with meta-regression. 286 participants received neuromuscular exercise (Table 1, study overview of neuromuscular exercise interventions), 508 participants received endurance exercise (Table 2, study overview of endurance exercise interventions), and 658 participants were allocated to control groups. The mean overall sample size was 53.8 participants per study ranging from 19 (42) to 121 (53) participants. All subjects were over 18 years old and either inpatients or outpatients. The training intervention period ranged from 10 days (48) to 32 weeks [i.e., (36)] with a training frequency ranging from 10 sessions in 10 days (48) to one session per week (31). Training session duration differed from 20 min (31) to 120 min (34). Training intensity was described with the Borg Scale in several studies (33, 44, 45), described in MET (50), described as a percentage of the one repetition maximum (38, 39), as a percentage of maximal heart rate (29, 42, 46, 48, 53), resting heart rate (40, 41, 47), or percentage of max. oxygen uptake (28, 49, 51, 52, 54). Two studies did not describe their exercise intensity (35, 36). Several involved randomized controlled trials with Tai- Chi or Yoga interventions also did not describe a specific exercise intensity thus we assumed that hatha yoga interventions count

| References | Study design   | Sample: Population, Sample<br>size ( <i>n</i> ), Age (years)  | Groups   | Intervention  | Training<br>characteristics   | Outcome<br>measures |
|------------|--|---|--|---|---|---------------------|
| (30)       | Randomized,<br>controlled trial                                  | Sedentary women with a BDI-II<br>score over 14, aged 18–50<br>years,<br>n = 26;<br>INT: 32.08 ± 9.11 year<br>CON: 32.38 ± 8.27 year   | INT (n = 13)<br>CON ( $n = 13$ )   | (a) INT, croup based yoga sessions with 5 min of<br>pranayama (breathing exercise), 5 min warm-up, 40 min<br>of asama (yoga poses) practice and 10 min of savasana<br>(meditation/relaxation). No intensity described,<br>assumption to be low to moderate intensity<br>(b) CON, instructed to maintain their usual level of<br>physical activity during the study duration                                 | 12 weeks, 2<br>sessions/week (24<br>training sessions);<br>each session<br>lasted 60 min  | BDI-II              |
| (29)       | Randomized,<br>controlled trial                                  | Women with diagnosed<br>depression (Research Diagnostic<br>criteria), aged 18–35 years<br>n = 40;<br>28.52 $\pm 4.36$ year            | NT $(n = 14)$<br>INT $(n = 15)$<br>3) CON $(n = 11)$   | <ul> <li>(a) INT, aerobic exercise prescription on the other overview</li> <li>(b) INT, 5–10 min warm-up, a standard 10-station program with a heart rate below50–60% of maximum heart rate and a 5–10 min cool-down period</li> <li>(c) CON, wait- list control group</li> </ul>   | 8 weeks, 4<br>sessions/week (32<br>training sessions);<br>no general<br>exercise duration   | BDI and HRSD        |
| (31)       | Randomized,<br>controlled trial                                  | Pregnant women with diagnostic criteria for depression on SCID, <40 years old, $n = 92$ ; INT: 24.4 ± 4.7 year CON: 26.0 ± 5.6 year   | INT (n = 46)<br>CON (n = 46)   | <ul> <li>(a) INT, yoga/tai- chi group sessions with a duration of<br/>20min. No intensity described, assumption that Tai- Chi<br/>lessons have moderate intensity</li> <li>(b) CON, wait- list control group; no intervention</li> </ul>  | 12 weeks, 1<br>session/week (12<br>training sessions);<br>each session<br>lasted 20 min   | CES-D               |
| (32)       | Comparative,<br>controlled trial with an<br>open- labeled design | Out-patients, fulfilled DSM-IV<br>criteria for MDD,<br><i>n</i> = 58;<br>33.65 y mean age   | INT ( $n = 15$ ), not in<br>meta- analysis<br>included<br>INT ( $n = 27$ )<br>CON ( $n = 16$ )   | (a) INT, yoga only, not in the meta- analysis involved<br>(b) INT, yoga lessons with a duration of 60 min per lesson<br>consisting of yogasana and breathing procedures. No<br>intensity described, assumption to be low to moderate<br>intensity. Furthermore, they received antide-pressant<br>medications with a dose defined by the treating<br>psychiatrist  | First 2 weeks daily<br>train- ing, next 2<br>weeks weekly<br>interval (16 training<br>ses- sions); each<br>session lasted<br>60 min | HRSD                |
| (33)       | Randomized,<br>controlled trial                                  | Older adults over 65 years, with<br>a GDS- score > 5,<br>n = 57;<br>76.53 ± 5.94 year   | INT ( $n = 19$ )<br>INT ( $n = 18$ ), not in<br>meta- analysis in-<br>cluded<br>CON ( $n = 20$ ) | (a) INT, physical exercises including a warm-up, cardio-<br>vascular exercises (walking with waving or clapping<br>hands), muscle strength exercises (triceps brachi, biceps<br>brachi, quadriceps femoris, iliopsoas) with a rated Borg<br>Scale score between 12 and 14 and a cool-down<br>(b) INT, cognitive behavioral therapy, not in meta-analysis<br>included<br>(c) CON, they receive no extra care | 12 weeks, 3<br>sessions/week (36<br>training sessions);<br>each session<br>lasted 50 min  | GDS-15              |
| (34)       | Randomized,<br>controlled trial                                  | Older adults over 60 years,<br>fulfilled DSM- IV criteria for MDD,<br>n = 73;<br>INT: 69.1 $\pm$ 7.0 year<br>CON: 72.0 $\pm$ 7.4 year | INT $(n = 36)$<br>CON $(n = 37)$   | <ul> <li>(a) INT, 2h of Tai Chi Chi; TCC employs "meditation<br/>through movement" No intensity described, assumption<br/>to be moderate intensity</li> <li>(b) Furthermore, they received 10 mg/day of<br/>escitalopram</li> <li>(c) CON, they received a Health Education Protocol.<br/>Furthermore, they received 10 mg/day of escitalopram</li> </ul>   | 10 weeks, 1<br>session/week (10<br>training sessions);<br>each session<br>lasted 120 min  | HRSD                |

(Continued)

| TABLE | TABLE 1   Continued |   |  |  |   |  |                     |
|-------|---------------------|---|--|--|---|--|---------------------|
|       | References          | Study design                                      | Sample: Population, Sample<br>size ( <i>n</i> ), Age (years)   | Groups   | Intervention  | Training<br>characteristics  | Outcome<br>measures |
| ~     | (35)                | Randomized,<br>controlled trial                   | Outpatient with a GDS- score ><br>10, aged over 53 years,<br><i>n</i> = 86;<br>NIT: 66.2 year<br>CON: 66.2 year                            | INT $(n = 43)$<br>CON $(n = 43)$                   | <ul> <li>(a) INT, exercise classes with predominantly weightbearing exercise performed to music. There was a warm-up period of 5-10 min and a cool-down period at the end. No intensity described</li> <li>(b) CON, they received twice weekly health education talks for 10 weeks</li> </ul>   | 10 weeks, 2<br>sessions/week (20<br>training sessions);<br>each session<br>lasted 45 min   | HRSD and GDS        |
| ω     | (36)                | Randomized,<br>naturalistic con- trolled<br>trial | Women, aged 40–60 years, fulfilled DSM- IV oriteria for MDD, $n = 30$ ; no mean age  | INT $(n = 10)$<br>CON $(n = 20)$                   | (a) INT, each session included a warm up (5 min),<br>physiological strengthening with machines (50 min) and a<br>cool-down (5 min). The exercise machines allowed<br>different exercises for arms, legs and postural muscles<br>and were changed every 4 min. There is no specific<br>exercise intensity described. Further- more, they<br>received pharmacological therapy<br>(b) CON, they only tot pharmacological therapy | 32 weeks, 2 ses-<br>sions/week (64<br>training sessions);<br>each session<br>lasted 60 min | d-mah               |
| თ     | (37)                | Randomized,<br>controlled pilot trial             | Aged over 18 years, diagnosis of<br>MDD,<br>n = 38;<br>43.4 ± 14.8 year  | INT $(n = 20)$<br>CON $(n = 18)$                   | (a) INT, 90- min practice sessions comprised of classical<br>yoga breathing techniques, mindful body postures and<br>final deep relaxation pose. No exercise intensity<br>described, assumption that hatha yoga is low intensity<br>exercise<br>(b) CON, 90-min education modules on yoga history and<br>philosophy   | 8 weeks, 2<br>sessions/week (16<br>training sessions);<br>each session<br>lasted 90 min    | BDI                 |
| 0     | (38)                | Randomized,<br>controlled trial                   | Aged 60 years or older, fulfilled<br>DSM- IV criteria for MDD,<br><i>n</i> = 32;<br>INT: 70 ± 1.5 year<br>CON: 72 ± 2.0 year               | INT (n = 17)<br>CON $(n = 15)$                     | (a) INT, a high intensity (80% of one repetition maximum)<br>progressive resistance training for the large muscle<br>groups with 3 sets of 8 repetitions on each machine. The<br>exercises included chest press, lat pulldown, leg press,<br>knee extension and knee flexion. (b) CON, control<br>subjects engaged in a health education program of<br>lectures and videos  | 10 weeks, 3<br>sessions/week (30<br>training sessions);<br>each session<br>lasted 50 min   | BDI                 |
| F     | (65)                | Randomized,<br>controlled trial                   | Aged 60–85 years, fulfilled<br>DSM-IV criteria for MDD,<br>n = 60;<br>INT: 69 $\pm 5$ year<br>INT: 70 $\pm 7$ year<br>CON: 69 $\pm 7$ year | INT $(n = 20)$<br>INT $(n = 20)$<br>CON $(n = 20)$ | <ul> <li>(c) INT, a high intensity (80% of one repetition maximum) progres- sive resistance training for the large muscle groups with 3 sets of 8 repetitions. Exercise machines included chest press, lat pulldown, leg press, knee extension and knee flexion</li> <li>(d) INT, same procedure as a) but with low- intensity (20% of one repetition maximum)</li> <li>(e) CON, received usual care</li> </ul>               | 8 weeks, 3<br>sessions/week (24<br>training sessions);<br>each session<br>lasted 65 min    | HRSD and GDS        |

| Reference | References Study design   | Sample: Population,<br>Sample size (n), Age<br>(years)  | Groups   | Intervention  | Training characteristics   | Outcome<br>measures |
|-----------|---|---|--|---|--|---------------------|
| (40)      | Randomized,<br>controlled trial, 3<br>arms                        | Older adults $\geq$ 50 years,<br>fulfilled DSM- IV criteria for<br>MDD, $n = 156; 57 \pm 6.5$ y   | INT ( $n = 55$ )<br>CON ( $n = 48$ )<br>Exercise only group not<br>in-volved in meta-<br>analysis                                    | <ul> <li>(a) INT, aerobic exercise sessions with a 10-min warm-up, 30 min walking or jogging with 70-85% of HRR and 5 min cool-down exercises; furthermore, patients received sertraline dosage of 50 mg up to 200 mg daily 200 mg daily</li> </ul>   | 16 weeks, 3 ses- sions/week (48 training sessions); each session lasted 45 min                 | HAMD-D<br>and BDI   |
| (41)      | Randomized,<br>parallel group, pla-<br>cebo-con- trolled<br>trial | Outpatients, fulfilled DSM-IV criteria for MID, aged over 40 years, $n = 202; 52 \pm 8$ y   | INT ( $n = 51$ )<br>CON ( $n = 49$ )<br>Medication<br>group and home-<br>based exercise group<br>not in- volved in meta-<br>analysis | <ul> <li>(a) INT, aerobic exercise sessions with a 10-min warmup, 30 min walking or jogging with 70–85% of HRR and 5 min cool-down exercises.</li> <li>(b) CON, received placebo- pills with a dosage of 50 mg up to 200 mg daily</li> </ul>  | 16 weeks, 3 ses- sions/week (48 training sessions); each session lasted 45 min                 | D-MAH               |
| (42)      | Randomized,<br>controlled trial, 2<br>arms                        | Women aged 18–65 years,<br>with ICD-10 diagnosis for<br>depres- sion, $n = 19$ ; INT:<br>52.78 $\pm$ 7.66 y CON: 47.80<br>$\pm$ 15.05 y | INT $(n = 9)$<br>CON $(n = 10)$  | <ul> <li>(a) NT, aerobic exercise sessions with a 10- min warm up, 30 min of aerobics with 65–75% of maximal heart rate and 5 min cool- down</li> <li>(b) CON, continued their usual pharmacological therapy but without any additional exercise to their habitual activities</li> </ul>  | 16 weeks, 3 session/week (48 training sessions); each session lasted 45–50 min                 | BDI-II              |
| (43)      | Not random- ized,<br>con- trolled trial                           | Women, aged 20–64 years,<br>with ICD-10 diagnosis for<br>depres- sion, $n = 82$ ; INT:<br>33.1 $\pm$ 5.4 y CON: 31.7 $\pm$<br>6.8 y     | INT (n = 41)<br>CON (n = 41)   | <ul> <li>(a) NT, progressive program of cardiovascular exercise with a warm-up, low-impact aerobics gyrmastics, fun dance and walking and a cool- down. Exercise inten- sity is not described but we assumed that low-impact exercises have moderate exercises intensity. Furthermore, the patients received 20 mg Fluoxetine</li> <li>(b) CON, only received 20 mg Fluoxetine</li> </ul> | 8 weeks, 3 sessions/ week (24 training sessions); session duration increased from 45 to 60 min | BDI                 |
| (44)      | Single-site, three-<br>armed,<br>randomized<br>controlled trial   | Adults, aged 18–65 years, fulfilled DSM- IV criteria for MDD, $n = 62$ ; INT: 44.7 $\pm$ 12.5 y CON: 46.3 $\pm$ 13.9 y                  | INT ( $h = 22$ )<br>INT ( $h = 20$ ), not in<br>meta-analysis included<br>CON ( $h = 20$ )   | (a) INT, aerobic exercise sessions with a warm- up phase<br>of 5-10 min, 45 min of interval training (inten- sity 16-17<br>on the Borg Scale) and 5 min cool- down phase with<br>stretching exercise<br>(b) INT, Basic Body Awareness Therapy (BBAT) inter-<br>vention, not involved in meta- analysis (c) CON,<br>participants only receive once advice and moti-                        | 8 weeks, 2 sessions/ week (16<br>training sessions); each session<br>lasted 60 min             | MADRS               |
| (45)      | Pragmatic,<br>randomized,<br>controlled trial                     | Adults, slightly over-weight,<br>aged 18–65 years, with<br>ICD-10 diagnosis of<br>depression, $n = 46$ ; 47.87<br>$\pm 10.47$           | INT ( $n = 30$ )<br>CON ( $n = 16$ )   | <ul> <li>(a) INT, sessions with 10–15 min warm-up, 30–40 min walk- ing/running (average Borg Scale Score 11.6) and 10–15 min cool-down. Participants could self- select the exercise intensity.</li> <li>(b) CON, no intervention</li> </ul>  | 8 weeks, 3 ses- sions/week (24<br>training sessions); each session<br>lasted 60 min            | BDI-II              |
| (29)      | Randomized,<br>controlled trial                                   | Women with diagnosed depression (Pesearch Diagnostic criteria), aged 18–35 years, $n = 40$ ; 28.52 $\pm 4.36$                           | INT ( $h = 14$ )<br>INT ( $h = 15$ )<br>CON ( $h = 11$ )   | <ul> <li>(a) INT, 5–10 min warm-up, walking or running with 80% of maximal work capacity on an indoor track, 5–10 min cool- down</li> <li>(b) INT, weight lift condition prescription CON, wait-list control group</li> </ul>   | 8 weeks, 4 ses- sions/week (32 training sessions); no general exercise duration                | HRSD and<br>BDI     |

|              |      | Keterences Study design                                   | sampre: ropuration,<br>Sample size (n), Age<br>(years)   | 2000   |   | Iraining characteristics  | Outcome<br>measures |
|--------------|------|---|--|--|---|---|---------------------|
| ω            | (46) | Randomized,<br>controlled, quasi-<br>experi- mental trial | Female students, diagnosed with MDD, aged 18–25 years, <i>n</i> = 20; No mean ae   | INT $(n = 10)$<br>CON $(n = 10)$   | (a) INT, 10 min warm-up, three sets of six min running<br>with moderate intensity (60–65% of maximal heart rate)<br>and 3 min relax- ing between the sets. Each week, 1 min<br>had been added to the run- ning time of each set<br>(b) CON, asked to pursue their normal life and do not<br>have any phys- ical activity during the intervention period       | 8 weeks, 3 ses- sions/week (24 training sessions); session duration in- creased from 40 to 60 min | BDI                 |
| Ø            | (47) | Randomized,<br>controlled trial                           | Adults, fulfilled the ICD- 10<br>criteria for MDD, aged<br>18–64 years, $n = 52$ ; INT:<br>4362 $\pm$ 13.3 y CON: 48.81<br>$\pm$ 11.3 y  | INT ( $n = 26$ )<br>CON ( $n = 26$ )   | (a) INT, 10 min warm-up, an interval- training exercise<br>regimen (upper and lower extremity exercise training)<br>with 3 bouts of 5- min workout with an intensity of<br>40-59% HRR. After the 5- min workouts, participants<br>exercised at a reduced intensity of 20-39% HRR for<br>5 min, making together 30 min of aero- bic interval<br>training       | 3 weeks, 5 ses- sions/week (15 training sessions); each session lasted 40 min                     | BDI and<br>MADRS    |
| 10           | (28) | Randomized,<br>controlled trial                           | Inpatients in the Hannover<br>Medical School, fulfilled<br>DSM-IV criteria for MDD, $n$<br>= 42; INT: 44.2 ± 8.5 y<br>CON: 40.9 ± 11.9 y | INT ( $n = 22$ )<br>CON ( $n = 20$ )   | (a) INT, exercise training with 25 min workout phase on a bicycle ergometer and 20 min with personal preference (cross-trainer, stepper, arm ergometer, treadmill, recumbent or rowing ergome- ter) with an intensity of 50% of maximum oxygen uptake (b) CON, could take part in the daily activity program of the ward (20 min in the morning)              | 6 weeks, 3 ses- sions/week (18<br>training sessions); each session<br>lasted 45 min               | BDI-II and<br>MADRS |
| ÷            | (48) | An open-ran-<br>domized, con-<br>trolled trial            | Adults, inpatients with a current antidepressant drug therapy, fulfilled DSM-IV criteria for MDD, $n = 35$ ; INT: 45.3 $\pm$ 13.2 y      | INT ( $n = 14$ )<br>INT ( $n = 11$ ), not<br>included in meta-<br>analysis<br>CON ( $n = 10$ ) | <ul> <li>(a) INT, aerobic exercise group; the intervention consisted of 30 min of daily brisk walking or jogging with an exercise intensity of 65–75% of age-predicted maximal heart rate</li> <li>(b) INT, stretching group; not included in meta- analysis</li> <li>(c) ON, participants received no intervention</li> </ul>                                | 10 days, one ses- sion/ day (10<br>train- ing sessions); each session<br>lasted 45 min            | BDI-II              |
| <u>6</u>     | (49) | Randomized,<br>controlled trial                           | Inpatients, aged 18–60 years, fulfilled DSM-IV criteria for MDD, $n = 43$ ; mean age 40 years  | INT (n = 24)<br>CON (n = 19)   | <ul> <li>(a) INT, a program of systematic aerobic exercise consisting of 1-h training with an intensity of 50–70% of maximal work capacity</li> <li>(b) CON, the control group attended occupational therapy while the training group exercised</li> </ul>  | 9 weeks, 3 sessions/week (27<br>training sessions), each session<br>lasted 60 min                 | BDI                 |
| <del>Ω</del> | (50) | Randomized,<br>controlled trial                           | Outpatients, aged 18–60 years, diagnosed for MDD.<br>n = 29;<br>INT: 48.68 $\pm$ 2.3 year<br>CON: 45.33 $\pm$ 3.11 year                  | INT (n = 19)<br>CON $(n = 10)$   | <ul> <li>(a) INT, 5 walks per week (1 was supervised on a treadmil) with 5 km/h average speed; Participants were asked to perform the remaining 4 walks with the same intensity. All patients were medicated with antidepressants</li> <li>(b) CON, were not assigned to take any exercise and remained taking their usual pharmacological therapy</li> </ul> | 12 weeks, 5 sessions/week (one was supervised); each walk lasted be- tween 30 and 45 min          | HAM-D 17            |

TABLE 2 | Continued

|    | Reference | References Study design                     | Sample: Population,<br>Sample size (n), Age<br>(years)  | Groups   | Intervention  | Training characteristics  | Outcome<br>measures |
|----|-----------|---|---|--|---|---|---------------------|
| 4  | (51)      | Randomized,<br>controlled trial             | Female smokers, aged 18-<br>55 years, with moderate to<br>severe depressive symp-<br>toms, $n = 30$ ; INT: 38.0 $\pm$<br>11.0 year CON: 37.0 $\pm$ 10.0<br>year | INT (n = 15)<br>CON ( $n = 15$ )                   | <ul> <li>(a) INT, participants exercised on cardiovascular equipment of their choice. Sessions comprised of a equipment of their choice. Sessions comprised of a 5-min warm-up, 20-30 min of aerobic activity and 5 min cool- down. Exercise was gradually progressed from moderate to vigorous intensity. Participants started with 20 min of vigorous exercise -&gt; by week 12, participants completed 3 sessions with 30 min of vigorous intensity (b) CON, they received health education lecture and films</li> </ul> | 12 weeks, 3 sessions/week (36 training sessions), each session lasted 30–40 min | 6. OHA              |
| Ω  | (52)      | Randomized,<br>controlled clinical<br>trial | Outpatients, aged 18 to 55 years, fulfilled DSM-IV criteria for MDD, $n = 57$ ; INT: 39.76 $\pm$ 11.6 year CON: 37.86 $\pm$ 9.85 year                           | INT $(n = 29)$<br>CON $(n = 28)$                   | <ul> <li>(a) INT, exercise session consisted of continuous and<br/>intermittent aerobic activ- ity with an intensity of 60%<br/>VO2 max at the beginning. Intensity progressively<br/>increased up to 85% of VO2max at the end<br/>Furthermore, patients started with the selective serotonin<br/>reuptake inhibitor sertraline (50 mg/day)</li> <li>(b) CON, patients only had the selective serotonin<br/>reuptake inhibitor sertraline (50 mg/day)</li> </ul>  | 4 weeks, 4 sessions/week (16 training sessions); no general exercise duration   | BDI and<br>HAM-D    |
| 10 | (53)      | Randomized,<br>controlled trial             | Aged between 65 and 85% years, sedentary, diagnosis of MDD, $n = 121$ ; INT: 75.0 $\pm$ 6.3 y INT: 75.0 $\pm$ 6.2 year CON: 75.6 $\pm$ 5.6 year                 | INT $(n = 37)$<br>INT $(n = 42)$<br>CON $(n = 42)$ | <ul> <li>(a) INT, 10 min warm-up, followed by cycling with an intensity that not exceed 70% of their peak heart rate and a 5-10 min cool-down. Patients reach 50 mg Sertraline within 2 weeks.</li> <li>(b) INT, 10 min warm-up, followed by cycling with an intensity that maintain the heart rate. The training range of 60% of peak heart rate. The training scheme increases in peak heart rate. Patients reach 50 mg Sertraline within 2 weeks.</li> <li>50 mg Sertraline within 2 weeks.</li> </ul>                   | 24 weeks, 3 sessions/week (72 training sessions); each session lasted 60 min    | HRSD                |
| 17 | (54)      | Randomized,<br>controlled trial             | Depressed patients aged<br>19–58 years, $n = 83$ ; mean<br>age 35.5 years   | INT $(n = 48)$<br>CON $(n = 35)$                   | <ul> <li>(a) INT, each session consisted of a warm-up routine and<br/>stretching exercises, followed by a running programme.<br/>Patients continued to receive the usual psychiatric<br/>treatment (supportive psychotherapy)</li> <li>(b) CON, Patients only continued to receive the usual<br/>psychiatric reatment as provided (supportive</li> </ul>  | 12 weeks, 3 super- vised<br>sessions/week; no exercise<br>duration pre- scribed | BD                  |

Nebiker et al.

Frontiers in Psychiatry | www.frontiersin.org

9

to low- intensity exercise (37), yogasana yoga interventions count to the low- to moderate intensity group (30, 32) and Tai- Chi interventions (31, 34) were grouped to the moderate intensity group. In studies using progressively increased exercise intensity (51, 52) we used the final exercise intensity during the intervention for the multivariate meta- regression analysis.

## Methodological Quality of the Included Studies

The mean study quality of the endurance intervention trials was 6.2 of the PEDro-scale with a range between 4 and 8 (**Table 3**). There was one trial (43) that distributed the participants into two age-balanced groups instead of randomization. Blinding of subjects and therapists has not been conducted, which is rather difficult within exercise intervention studies.

The mean study quality of the neuromuscular intervention trials was 6.6 with a range between 4 and 8 (**Table 4**). Thus, overall study quality did not differ between endurance and neuromuscular training. There was also one trial (32) without randomization. Only (30) blinded the therapist.

The overall mean PEDro score including all endurance and neuromuscular intervention trials was 6.41 with a range between 4 and 8 (**Tables 3**, **4**). Twenty out of twenty seven included studies reached the determined cut-off PEDro score of  $\geq 6$  and therefore, we can generally evaluate the quality of the included studies as strong enough to be methodological sound.

### **Risk of Bias Assessment**

The funnel plot of the endurance intervention studies (Figure 2) shows an asymmetrical plot and therefore a publication bias cannot be ruled out. It might be plausible that studies with severely depressed patient that did not complete exercise training or refrained from doing it, are not published. Moreover, the control groups underwent other therapies, also pharmacotherapy, this is a considerable bias with lack of stratification. Further analysis revealed that there are several smaller studies (relating to the number of participants), of which results are biased toward larger beneficial effects (29, 42, 46, 48). These studies presented a PEDro score between of five or six, which is below the overall mean score of 6.41. The study of de la Cerda et al. (43) with its effect size of -2.7 attracts also our attention in this funnel plot and is explainable with the low PEDro score and missing randomization.

The funnel plot of neuromuscular intervention studies (Figure 2, plot a) shows a middle asymmetrical funnel shape because smaller studies showing no beneficial effects are missing.

# Effectiveness of an Exercise Intervention for Depression

The results of our meta-analysis with all included studies (**Figure 3**) show a large effect size of g = -0.93 (90% CI: -1.17 to -0.70); p < 0.00001,  $I^2 = 83\%$ . Heterogeneity can be considered high ( $I^2 = 83\%$ ).

Further, we conducted a sensitivity analysis due to the methodological weakness of several studies with the assumption

| Author | Eligibility<br>specified | Subjects<br>randomly<br>allocated | Concealed<br>allocation | Concealed Similar baseline Blinding of<br>allocation values subjects | Blinding of<br>subjects | Blinding of<br>therapist | Blinding of<br>assessor | Blinding of Dropout <15%Received<br>assessor treatment<br>as allocat | <ul><li>Received</li><li>treatment</li><li>as allocated</li></ul> | Statistical<br>between- group<br>comparison | Point measures Sum (2-11)<br>and variability<br>provided | Sum (2-11 |
|--------|--------------------------|-----------------------------------|-------------------------|--|-------------------------|--------------------------|-------------------------|--|---|---|--|-----------|
| (41)   | +                        | +                                 | +                       | +  | I                       | I                        | +                       | +  | +   | +   | +  | œ         |
| _      | +                        | +                                 | +                       | +  | I                       | I                        | +                       | I  | +   | +   | +  | 7         |
|        | +                        | +                                 | I                       | +  | I                       | I                        | I                       | I  | +   | +   | +  | ß         |
|        | +                        | +                                 | +                       | +  | I                       | I                        | +                       | I  | +   | +   | +  | 7         |
|        | +                        | I                                 | I                       | +  | I                       | I                        | I                       | +  | +   | +   | +  | Q         |
|        | +                        | +                                 | I                       | +  | I                       | I                        | I                       | I  | +   | +   | +  | ß         |
|        | +                        | +                                 | I                       | +  | I                       | I                        | +                       | I  | I   | +   | +  | Q         |
|        | I                        | +                                 | +                       | +  | I                       | I                        | I                       | I  | +   | +   | +  | 9         |
|        | +                        | +                                 | +                       | +  | I                       | I                        | +                       | I  | +   | +   | +  | 7         |
|        | +                        | +                                 | I                       | +  | I                       | I                        | I                       | +  | +   | +   | +  | 9         |
|        | +                        | +                                 | I                       | +  | I                       | I                        | I                       | +  | +   | +   | +  | 9         |
|        | +                        | +                                 | +                       | +  | I                       | I                        | I                       | +  | I   | +   | +  | 9         |
|        | +                        | +                                 | +                       | I  | I                       | I                        | +                       | +  | I   | +   | +  | 9         |
|        | +                        | +                                 | +                       | +  | I                       | I                        | +                       | +  | +   | +   | +  | Ø         |
|        | +                        | +                                 | +                       | +  | I                       | I                        | +                       | I  | +   | +   | +  | 7         |
| (53)   | +                        | +                                 | I                       | +  | I                       | I                        | +                       | +  | +   | +   | +  | 7         |
|        | _                        | +                                 | I                       | I  | I                       | 1                        | _                       | 1  | I   | -   | -  | 7         |

**TABLE 3** | PEDro scores and sum of the included endurance intervention trials

| Author | Author Eligibility<br>Specified | Subjects<br>randomly | Concealed<br>allocation | Similar<br>baseline | Blinding of<br>subjects | Blinding of<br>therapist | Blinding of<br>assessor | Dropout<br><15% | Received<br>treatment | Statistical between-<br>group comparison | Statistical between- Point measures and Sum(2-11 group comparison variability provided | Sum(2-11) |
|--------|---------------------------------|----------------------|-------------------------|---------------------|-------------------------|--------------------------|-------------------------|-----------------|-----------------------|--|--|-----------|
|        |                                 | allocated            |                         | values              |                         |                          |                         |                 | as allocated          |  |  |           |
| (30)   | +                               | +                    | +                       | +                   | I                       | +                        | +                       | I               | +                     | +  | +  | 80        |
| (29)   | +                               | +                    | I                       | +                   | I                       | I                        | +                       | I               | Ι                     | +  | +  | 5         |
| (31)   | +                               | +                    | I                       | +                   | I                       | I                        | I                       | I               | +                     | +  | +  | 4         |
| (32)   | +                               | I                    | +                       | +                   | I                       | I                        | +                       | +               | Ι                     | +  | +  | 9         |
| (33)   | +                               | +                    | I                       | +                   | I                       | I                        | +                       | +               | +                     | +  | +  | 7         |
| (34)   | +                               | +                    | +                       | +                   | I                       | I                        | +                       | +               | +                     | +  | +  | 00        |
| (35)   | +                               | +                    | +                       | +                   | I                       | I                        | +                       | +               | I                     | +  | +  | 7         |
| (36)   | +                               | +                    | I                       | +                   | I                       | I                        | I                       | +               | +                     | +  | +  | 9         |
| (37)   | +                               | +                    | +                       | +                   | I                       | I                        | +                       | I               | +                     | +  | +  | 7         |
| (38)   | +                               | +                    | +                       | +                   | I                       | I                        | +                       | +               | +                     | +  | +  | 00        |
| (39)   | +                               | +                    | +                       | +                   | I                       | I                        | +                       | +               | I                     | 4  | 4  | 7         |

that the effect size could be exaggerated in favor of exercise. The pooled data from all included studies with good methodological quality (studies with a PEDro score  $\geq 6$ ) still showed a large significant improvement in favor of exercise interventions compared to the control condition [SMD: -0.83 (90% CI: -1.13 to -0.54); p < 0.00001,  $I^2 = 79\%$ ; **Figure 4**]. Heterogeneity can be considered high ( $I^2 = 79\%$ ). Interestingly, neuromuscular training seems to induce significantly higher effects compared to endurance training when considering only strong studies (**Figure 4**; p = 0.04,  $I^2 = 76.7\%$ ).

### Sensitivity Analysis of the Effectiveness of Endurance Exercise Interventions


The results of the present meta-analysis show moderate to large effects in favor of endurance exercise interventions compared to the control condition [SMD: -0.79 (90% CI: -1.10 to - 0.48); p < 0.00001,  $I^2 = 84\%$ ; Figure 3]. Heterogeneity can be considered high ( $I^2 = 84\%$ ). As explained before and already seen in the funnel plots, risk of bias assessment indicates that weaker studies [PEDro  $\leq$  5, SMD: -1.32 (90% CI: -2.22 to -0.42), Figure 5] tend to enlarge the effect sizes compared to stronger studies (PEDro  $\geq$  6, SMD: -0.55 (90% CI: -0.82 to -0.29), Figure 5]. Hence regarding the stronger studies, the effect size is still moderate in favor of endurance exercise interventions compared to control condition.

## Sensitivity Analysis of the Effectiveness of Neuromuscular Exercise Interventions

Very large effects were found in favor of neuromuscular exercise interventions compared to the control condition [SMD: -1.14 (90% CI: -1.50 to -0.78); p < 0.00001,  $I^2 = 80\%$ ; Figure 3]. Heterogeneity can be considered high  $(I^2 = 80\%)$ . Risk of bias assessment revealed that weaker studies [PEDro  $\leq$  5, SMD: -0.99 (90% CI: -1.83 to -0.16), Figure 5] tend to attenuate the effect sizes compared to stronger studies [PEDro  $\geq 6$ , SMD: -1.19 (90% CI: -1.61 to -0.76), Figure 5]. Interestingly, the effect tended to be slightly larger in favor of strength/resistance training [SMD: -1.42 (90% CI: -2.21 to -0.64)] compared to Yoga/Tai-Chi approaches [SMD: -1.14 (90% CI: -1.57 to -0.72)]. This finding did not change when adjusting for study quality and strengthened the assumption that neuromuscular training, particularly strength/resistance training can induce superior effects compared to endurance training.

### Meta-Regression Analysis for Effects of Endurance Training Prescriptors

A summary of the results of the multivariate meta-regression analysis in endurance interventions is presented in **Table 5**. Number of exercise sessions, exercise intensity and frequency of exercise sessions did not moderate the antidepressant effect of endurance exercise interventions. Only exercise duration notably moderated the effect of endurance interventions. An extended exercise duration of 10 min





| Study or Subgroup  | Std. Mean Difference   | SE  | Total  | Total  | Weight   | IV, Random, 90% CI  | IV, Random, 90% CI                       |
|--|--|---|--|--|--|---|--|
| 1.1.1 Endurance Intervention   | ons  |   |  |  |  |   |  |
| Carneiro 2015  | -1.33  | 0.51  | 9  | 10   | 2.8%   | -1.33 [-2.17, -0.49]  |  |
| Hemat- Far 2012  | -1.41  | 0.5   | 10   | 10   | 2.8%   | -1.41 [-2.23, -0.59]  |  |
| Doyne 1987   | -1.83  | 0.49  | 14   | 11   | 2.9%   | -1.83 [-2.64, -1.02]  |  |
| Legrand 2015   | -1.66  | 0.48  | 14   | 10   |  | -1.66 [-2.45, -0.87]  |  |
| Mota-Pereira et al. (2011)   | -1.02  | 0.41  | 19   | 10   | 3.2%   | -1.02 [-1.69, -0.35]  |  |
| Patten 2016  | 0.06   | 0.37  | 15   | 15   | 3.4%   | 0.06 [-0.55, 0.67]  |  |
| Danielsson 2014  | -1.23  | 0.34  | 22   | 20   | 3.5%   | -1.23 [-1.79, -0.67]  |  |
| Martinsen 1985   | -0.69  | 0.32  | 24   | 19   | 3.6%   | -0.69 [-1.22, -0.16]  |  |
| Doose 2015   | -0.75  | 0.32  | 30   | 16   | 3.6%   | -0.75 [-1.28, -0.22]  |  |
| De la Cerda 2011   | -2.7   | 0.31  | 41   | 41   | 3.6%   | -2.70 [-3.21, -2.19]  |  |
| Kerling 2015   | -0.32  | 0.31  | 22   | 20   | 3.6%   | -0.32 [-0.83, 0.19]   |  |
| W.H. Ho 2014   | -0.39  | 0.28  | 26   | 26   | 3.7%   | -0.39 [-0.85, 0.07]   |  |
| Siqueira 2016  | -0.01  | 0.26  | 29   | 28   | 3.8%   | -0.01 [-0.44, 0.42]   | +  |
| Toni 2015  | -0.87  | 0.24  | 37   | 42   | 3.9%   | -0.87 [-1.26, -0.48]  | -  |
| Veale et al. (1992)  | -0.08  | 0.22  | 48   | 35   | 4.0%   | -0.08 [-0.44, 0.28]   | +  |
| Blumenthal 1999  | 0.23   | 0.2   | 55   | 48   | 4.0%   | 0.23 [-0.10, 0.56]  | +-                                       |
| Blumenthal 2007  | -0.27  | 0.2   | 51   | 49   | 4.0%   | -0.27 [-0.60, 0.06]   | -  |
| Subtotal (90% CI)  |  |   | 466  | 410  | 59.5%  | -0.79 [-1.10, -0.48]  | •  |
| Test for overall effect: $Z = 4$   | .18 (P < 0.0001)   |   |  |  |  |   |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Interv   | .18 (P < 0.0001)<br>ventions   |   |  |  | 2.4%   | _3 83 [_4 83 _2 83]   |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Interv<br>Singh 1997   | .18 (P < 0.0001)   | 0.61  | 17<br>15   | 19<br>11   |  | -3.83 [-4.83, -2.83]<br>-1.59 [-2.35, -0.83]  |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Interv<br>Singh 1997<br>Doyne 1987   | .18 (P < 0.0001)<br>ventions<br>-3.83  | 0.61<br>0.46  | 17   | 19   | 3.0%   | -1.59 [-2.35, -0.83]  |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Interv<br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59   | 0.61<br>0.46<br>0.44  | 17<br>15   | 19<br>11   | 3.0%<br>3.1%   |   |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Intern<br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007  | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08  | 0.61<br>0.46<br>0.44<br>0.44  | 17<br>15<br>15   | 19<br>11<br>10   | 3.0%<br>3.1%<br>3.1%   | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54   | 0.61<br>0.46<br>0.44<br>0.44<br>0.44  | 17<br>15<br>15<br>10   | 19<br>11<br>10<br>20   | 3.0%<br>3.1%<br>3.1%<br>3.2%   | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Interv</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.88   | 0.61<br>0.46<br>0.44<br>0.44<br>0.44  | 17<br>15<br>15<br>10<br>13   | 19<br>11<br>10<br>20<br>13   | 3.0%<br>3.1%<br>3.1%<br>3.2%<br>3.3%   | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]<br>-0.82 [-1.49, -0.15]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.88   | 0.61<br>0.46<br>0.44<br>0.44<br>0.41<br>0.4<br>0.36                                   | 17<br>15<br>15<br>10<br>13<br>18   | 19<br>11<br>10<br>20<br>13<br>19   | 3.0%<br>3.1%<br>3.1%<br>3.2%<br>3.3%<br>3.4%                                 | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]<br>-0.82 [-1.49, -0.15]<br>-1.88 [-2.54, -1.22]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.88<br>-1   | 0.61<br>0.46<br>0.44<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33                           | 17<br>15<br>15<br>10<br>13<br>18<br>17   | 19<br>11<br>10<br>20<br>13<br>19<br>19                                       | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.4%<br>3.5%                                 | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]<br>-0.82 [-1.49, -0.15]<br>-1.88 [-2.54, -1.22]<br>-1.00 [-1.59, -0.41]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013   | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.54<br>-0.82<br>-1.54<br>-0.82<br>-1.88<br>-1<br>-0.67   | 0.61<br>0.46<br>0.44<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33<br>0.3                    | 17<br>15<br>15<br>10<br>13<br>18<br>17<br>19   | 19<br>11<br>10<br>20<br>13<br>19<br>19<br>20                                 | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.4%<br>3.5%<br>3.7%                         | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]<br>-0.82 [-1.49, -0.15]<br>-1.88 [-2.54, -1.22]<br>-1.00 [-1.59, -0.41]<br>-0.67 [-1.21, -0.13]  |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikani 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013<br>Lavretsky 2011  | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.54<br>-0.82<br>-1.54<br>-0.82<br>-1.88<br>-1<br>-0.67<br>-0.61  | 0.61<br>0.46<br>0.44<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33<br>0.3<br>0.26            | 17<br>15<br>10<br>13<br>18<br>17<br>19<br>27   | 19<br>11<br>10<br>20<br>13<br>19<br>19<br>20<br>16                           | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.4%<br>3.5%<br>3.7%                         | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.26, -0.82]<br>-0.82 [-1.49, -0.15]<br>-1.88 [-2.54, -1.22]<br>-1.00 [-1.59, -0.41]<br>-0.67 [-1.21, -0.13]<br>-0.61 [-1.10, -0.12]  |  |
| Heterogeneity: Tau <sup>2</sup> = 0.49;<br>Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013<br>Lavretsky 2011<br>Mather 2002<br>Field 2012<br>Subtotal (90% CI)  | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.88<br>-1<br>-0.67<br>-0.61<br>-1.31<br>-1.31<br>-1.32<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54<br>-1.54 | 0.61<br>0.46<br>0.44<br>0.44<br>0.41<br>0.36<br>0.33<br>0.3<br>0.26<br>0.22           | 17<br>15<br>15<br>10<br>13<br>18<br>17<br>19<br>27<br>36   | 19<br>11<br>10<br>20<br>13<br>19<br>19<br>20<br>16<br>37                     | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.4%<br>3.5%<br>3.7%<br>3.8%<br>4.0%<br>4.0% | $\begin{array}{c} -1.59 \left[ -2.35, -0.83 \right] \\ -1.08 \left[ -1.80, -0.36 \right] \\ -1.54 \left[ -2.26, -0.82 \right] \\ -0.82 \left[ -1.49, -0.15 \right] \\ -1.88 \left[ -2.54, -1.22 \right] \\ -1.00 \left[ -1.59, -0.41 \right] \\ -0.67 \left[ -1.21, -0.13 \right] \\ -0.61 \left[ -1.10, -0.12 \right] \\ -1.31 \left[ -1.74, -0.88 \right] \\ -0.06 \left[ -0.42, 0.30 \right] \\ -0.56 \left[ -0.91, -0.21 \right] \end{array}$ |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013<br>Lavretsky 2011<br>Mather 2002<br>Field 2012  | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.54<br>-0.67<br>-0.61<br>-1.31<br>-0.06<br>-0.56<br>; Chi <sup>2</sup> = 54.77, df = 11   | 0.61<br>0.46<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33<br>0.3<br>0.26<br>0.22<br>0.21    | 17<br>15<br>15<br>10<br>13<br>18<br>17<br>19<br>27<br>36<br>42<br>46<br>275  | 19<br>11<br>10<br>20<br>13<br>19<br>20<br>16<br>37<br>43<br>46<br><b>273</b> | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.4%<br>3.5%<br>3.7%<br>3.8%<br>4.0%<br>4.0% | $\begin{array}{c} -1.59 \ [-2.35, -0.83] \\ -1.08 \ [-1.80, -0.36] \\ -1.54 \ [-2.26, -0.82] \\ -0.82 \ [-1.49, -0.15] \\ -1.88 \ [-2.54, -1.22] \\ -1.00 \ [-1.59, -0.41] \\ -0.67 \ [-1.21, -0.13] \\ -0.61 \ [-1.10, -0.12] \\ -1.31 \ [-1.74, -0.88] \\ -0.66 \ [-0.42, 0.30] \end{array}$  |  |
| Test for overall effect: Z = 4<br>1.1.2 Neuromuscular Intern<br>Singh 1997<br>Doyne 1987<br>Prathikanti 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013<br>Lavretsky 2011<br>Mather 2002<br>Field 2012<br>Subtotal (90% CI)<br>Heterogeneity: Tau <sup>2</sup> = 0.43;<br>Test for overall effect: Z = 5<br>Total (90% CI) | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.88<br>-1<br>-0.67<br>-0.61<br>-1.31<br>-0.06<br>-0.56<br>; Chi <sup>2</sup> = 54.77, df = 11<br>.26 (P < 0.00001)  | 0.61<br>0.46<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33<br>0.26<br>0.22<br>0.21<br>(P < 0 | 17<br>15<br>15<br>10<br>13<br>18<br>17<br>19<br>27<br>36<br>42<br>46<br>275<br>00001); l <sup>2</sup> = 809<br>741 | 19<br>11<br>10<br>20<br>13<br>19<br>20<br>16<br>37<br>46<br><b>273</b><br>%  | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.3%<br>3.5%<br>3.7%<br>3.8%<br>4.0%<br>4.0% | $\begin{array}{c} -1.59 \left[ -2.35, -0.83 \right] \\ -1.08 \left[ -1.80, -0.36 \right] \\ -1.54 \left[ -2.26, -0.82 \right] \\ -0.82 \left[ -1.49, -0.15 \right] \\ -1.88 \left[ -2.54, -1.22 \right] \\ -1.00 \left[ -1.59, -0.41 \right] \\ -0.67 \left[ -1.21, -0.13 \right] \\ -0.61 \left[ -1.10, -0.12 \right] \\ -1.31 \left[ -1.74, -0.88 \right] \\ -0.06 \left[ -0.42, 0.30 \right] \\ -0.56 \left[ -0.91, -0.21 \right] \end{array}$ |  |
| Test for overall effect: Z = 4<br><b>1.1.2 Neuromuscular Intern</b><br>Singh 1997<br>Doyne 1987<br>Prathikani 2017<br>Pilu 2007<br>Chu 2017<br>Singh 2005 (1)<br>Singh 2005 (2)<br>Huang 2015<br>Gangadhar 2013<br>Lavretsky 2011<br>Mather 2002<br>Field 2012<br>Subtotal (90% CI)<br>Heterogeneity: Tau <sup>2</sup> = 0.43;<br>Test for overall effect: Z = 5             | .18 (P < 0.0001)<br>ventions<br>-3.83<br>-1.59<br>-1.08<br>-1.54<br>-0.82<br>-1.54<br>-0.67<br>-0.61<br>-1.31<br>-0.06<br>(Chl <sup>2</sup> = 54.77, df = 11<br>.26 (P < 0.0001)<br>Chl <sup>2</sup> = 164.60, df = 28   | 0.61<br>0.46<br>0.44<br>0.41<br>0.4<br>0.36<br>0.33<br>0.26<br>0.22<br>0.21<br>(P < 0 | 17<br>15<br>15<br>10<br>13<br>18<br>17<br>19<br>27<br>36<br>42<br>46<br>275<br>00001); l <sup>2</sup> = 809<br>741 | 19<br>11<br>10<br>20<br>13<br>19<br>20<br>16<br>37<br>46<br><b>273</b><br>%  | 3.0%<br>3.1%<br>3.2%<br>3.3%<br>3.3%<br>3.5%<br>3.7%<br>3.8%<br>4.0%<br>4.0% | -1.59 [-2.35, -0.83]<br>-1.08 [-1.80, -0.36]<br>-1.54 [-2.56, -0.82]<br>-0.82 [-1.49, -0.15]<br>-1.88 [-2.54, -1.22]<br>-1.00 [-1.59, -0.41]<br>-0.67 [-1.21, -0.13]<br>-0.61 [-1.10, -0.12]<br>-1.31 [-1.74, -0.88]<br>-0.06 [-0.42, 0.30]<br>-0.56 [-0.91, -0.21]<br>-1.14 [-1.50, -0.78]   | Favours (experimental) Favours (control) |

independent variable.

resulted in a significant antidepressant effect size increase of  $-0.62.\,$ 

### Meta-Regression Analysis for Effects of Endurance Training Prescriptors

A summary of all meta-regression analyses in neuromuscular interventions is presented in **Table 6**. Number of exercise

sessions, frequency of exercise sessions and exercise session duration did not moderate the antidepressant effect of neuromuscular exercise interventions. Only exercise intensity moderated the effect of neuromuscular interventions. An increased exercise intensity of 10% resulted in a significant increased antidepressant effect size of -0.54.

| Study or Subgroup  | Std. Mean Difference   | SE     | Total Total                 | Weight  | IV, Random, 90% CI   | IV, Random, 90% CI                       |
|--|------------------------|--------|-----------------------------|---------|----------------------|--|
| 1.3.1 Strong Pedro Score E                                       | ndurance Interventions |        |                             |         |                      |  |
| Hemat- Far 2012  | -1.41                  | 0.5    | 10 10                       | 3.6%    | -1.41 [-2.23, -0.59] |  |
| Legrand 2015   | -1.66                  | 0.48   | 14 10                       | 3.7%    | -1.66 [-2.45, -0.87] |  |
| Mota-Pereira et al. (2011)                                       | -1.02                  | 0.41   | 19 10                       | 4.2%    | -1.02 [-1.69, -0.35] |  |
| Patten 2016  | 0.06                   | 0.37   | 15 15                       | 4.4%    | 0.06 [-0.55, 0.67]   | _ <b>_</b>                               |
| Danielsson 2014  | -1.23                  | 0.34   | 22 20                       | 4.6%    | -1.23 [-1.79, -0.67] |  |
| Martinsen 1985   | -0.69                  | 0.32   | 24 19                       | 4.7%    | -0.69 [-1.22, -0.16] |  |
| Kerling 2015   | -0.32                  | 0.31   | 22 20                       | 4.8%    | -0.32 [-0.83, 0.19]  |  |
| W.H. Ho 2014   | -0.39                  | 0.28   | 26 26                       | 5.0%    | -0.39 [-0.85, 0.07]  |  |
| Siqueira 2016  | -0.01                  | 0.26   | 29 28                       | 5.1%    | -0.01 [-0.44, 0.42]  |  |
| Toni 2015  | -0.87                  | 0.24   | 37 42                       | 5.2%    | -0.87 [-1.26, -0.48] |  |
| Blumenthal 1999  | 0.23                   | 0.2    | 55 48                       | 5.5%    | 0.23 [-0.10, 0.56]   | +  |
| Blumenthal 2007  | -0.27                  | 0.2    | 51 49                       |         |                      |  |
| Subtotal (95% CI)  |                        |        | 324 297                     | 56.2%   | -0.55 [-0.87, -0.24] | •  |
| Heterogeneity: Tau <sup>2</sup> = 0.21;                          |                        | P  < 0 | $0001$ ; $I^2 = 71\%$       |         |                      |  |
| Test for overall effect: Z = 3                                   | .43 (P = 0.0006)       |        |                             |         |                      |  |
|  |                        |        |                             |         |                      |  |
| 1.3.2 Strong Pedro Score N                                       |                        |        |                             |         |                      |  |
| Singh 1997   | -3.83                  |        | 17 19                       |         | -3.83 [-4.83, -2.83] |  |
| Prathikanti 2017   | -1.08                  |        | 15 10                       |         | -1.08 [-1.80, -0.36] |  |
| Pilu 2007  | -1.54                  |        | 10 20                       |         | -1.54 [-2.26, -0.82] |  |
| Chu 2017   | -0.82                  |        | 13 13                       |         | -0.82 [-1.49, -0.15] |  |
| Singh 2005 (1)   | -1.88                  |        | 18 19                       |         | -1.88 [-2.54, -1.22] |  |
| Singh 2005 (2)   |                        | 0.36   | 17 19                       |         | -1.00 [-1.59, -0.41] |  |
| Huang 2015   | -0.67                  |        | 19 20                       |         | -0.67 [-1.21, -0.13] |  |
| Gangadhar 2013   | -0.61                  |        | 27 16                       |         | -0.61 [-1.10, -0.12] |  |
| Lavretsky 2011   | -1.31                  |        | 36 37                       |         | -1.31 [-1.74, -0.88] |  |
| Mather 2002  | -0.06                  | 0.22   | 42 43                       |         | -0.06 [-0.42, 0.30]  | ▲ <sup>+</sup>                           |
| Subtotal (95% CI)  |                        |        | 214 216                     | 43.8%   | -1.19 [-1.70, -0.68] | -  |
| Heterogeneity: Tau <sup>2</sup> = 0.53                           |                        | < 0.0  | $0001$ ; $l^2 = 82\%$       |         |                      |  |
| Test for overall effect: $Z = 4$                                 | .56 (P < 0.00001)      |        |                             |         |                      |  |
| Total (95% CI)   |                        |        | 538 513                     | 100.0%  | -0.83 [-1.13, -0.54] | •  |
| Heterogeneity: $Tau^2 = 0.37$                                    | Chi2 102 05 df - 21    | (D     |                             | 100.070 | -0.05 [-1.15, -0.54] | <b>~</b>                                 |
|  |                        | (P <   | $1.00001$ ; $1^{-} = 7.9\%$ |         |                      | -4 -2 0 2 4                              |
| Test for everall offerts 7 - F                                   |                        |        | 4) 12 - 76 70               |         |                      | Favours [experimental] Favours [control] |
| Test for overall effect: $Z = 5$                                 |                        |        |                             |         |                      |  |
| Test for overall effect: $Z = 5$<br>Test for subgroup difference | 4.28,  dr = 1          | - 0.1  | 4), 1 = 70.7%               |         |                      |  |

### DISCUSSION

To the best of our knowledge, this is the first meta-analytical review with meta-regression that examined the differential effects of endurance vs. neuromuscular exercise interventions for the treatment of depression taking exercise training prescriptors and study quality into account. A differentiation between neuromuscular and endurance exercise seems beneficial as patients do have different exercise preferences and both exercise modes cause different adaptations on behavioral and molecular level (24). The general effect size of exercise interventions compared to control group conditions was large. Due to methodological issues of some included studies, this effect size can be potentially biased in favor of exercise. A follow-up sensitivity analysis including only methodological sound (PEDro score  $\geq 6$ ) studies led to a reduced, but still large effect size of g = -0.83 (see Figure 4). In a second step, the effects of neuromuscular exercise intervention studies as well as endurance exercise intervention studies were investigated and compared to the control condition. Our analyses revealed significant moderate effects for the methodological strong studies for endurance exercise interventions and significant large effects for the methodological strong studies for neuromuscular exercise interventions, respectively. Interestingly, effect sizes significantly differed in favor of neuromuscular exercise training compared to endurance training when only analyzing strong studies. Our multivariate meta-regression analysis for the different exercise training prescriptors revealed potential moderator variables. We found that exercise duration significantly moderates the effect of endurance interventions and exercise intensity moderates notably the effect of neuromuscular interventions.

# Exercise Interventions and Depressive Outcome

Our meta-analysis suggests a large significant overall effect size of g = -0.83 for the methodological stronger studies. Previous meta-analyses generally underpin a large effect in favor of exercise based on calculating standardized mean differences. For example, Schuch et al. (20) found an effect size of SMD = 0.98 (95% CI: 0.68-1.28). This effect size was underestimated due to publication bias and was recalculated to 1.11 (95% CI: 0.79-1.43). Schuch et al. (20) noted that the greater effect size in patients diagnosed with MDD results from greater baseline depression scores and a greater potential to reach a larger reduction in depressive symptoms. Compared to our meta-analysis, they did not exclude studies with participants suffering from other chronic illnesses than MDD in their metaanalysis. The meta-analysis of Josefsson et al. (16) showed an effect size of g = -0.77 (95% CI: -1.14 to -0.41) and was strengthened by a sensitivity analysis including only studies using intention-to-treat analyses (g = -0.70 with 95% CI: -1.03 to -0.38). In line with our findings, further analyses of Josefsson et al. (16) considering only methodological strong studies led to a substantially reduced effect size of g = -0.43 (95% CI: -1.06 to 0.21) indicating a moderate but no more a large effect size. They considered methodological quality as being

| 12.1 wak pedio score neuromuscular trials  Down 1987 - 1.59 (-2.35, -0.83) - 1.50 (-2.1, -0.56 (-2.1, -0.21) - 0.56 (-2.1, -0.21) - 0.56 (-2.1, -0.21) - 0.55 (-2.0, -0.21) -   | Study or Subgroup Std                                    | Mean Difference SE                  | rimental C<br>Total      |     |        | Std. Mean Difference<br>IV, Random, 90% CI | Std. Mean Difference<br>IV, Random, 90% CI |
|--|--|-------------------------------------|--------------------------|-----|--------|--|--|
| Field 2012 - 0.56 0.21 46 46 4.0% -0.55 [0.21] -0.21<br>61 57 7.0% -0.99 [-1.83, -0.21] 45<br>Heterogeneity: Tau <sup>2</sup> = 0.40; Ch <sup>2</sup> = 4.15, df = 1 (P = 0.04); l <sup>2</sup> = 76%<br>Tast for overall effect Z = 1.95 (P = 0.05)<br>1.2.2 strong pedro score neuromusular trials<br>Singh 1997 - 1.54 0.44 10 20 3.1% -1.54 [-2.26, -0.82]<br>Prathikant 2017 - 1.08 0.44 15 10 3.1% 1.54 [-2.26, -0.85]<br>Prathikant 2017 - 0.82 0.41 13 13 3.2% -0.82 [-1.49, -0.15]<br>Singh 2005 (1) - 1.88 0.4 18 19 3.3% -1.88 [-2.48, -1.22]<br>Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 - 0.66 1.0.3 27 16 3.7% -0.66 [-1.10, -0.12]<br>Huards 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Huards 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Huards 2012 - 0.06 0.22 42 42 33.5% -1.06 [-1.40, -0.88]<br>Huards 2022 - 0.06 0.22 42 42 43 3.5% -1.06 [-1.40, -0.88]<br>Huards 2022 - 0.06 0.22 42 42 43 3.5% -0.57 [-1.28, -0.22]<br>Fast for overall effect Z = 4.56 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 23%<br>Test for overall effect Z = 4.56 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 23%<br>Test for overall effect Z = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 1.44; df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 3.43 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 3.63, df = 11 (P < 0.00001); l <sup>2</sup> = 71%<br>Test for overall effect Z = 3.43 (P = 0.0006)<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 3.63, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect Z = 3.43 (P = 0.0006) |  |                                     |                          |     |        | ,  |  |
| Field 2012 - 0.56 0.21 46 46 4.0% -0.55 [0.21] -0.21<br>61 57 7.0% -0.99 [-1.83, -0.21] 45<br>Heterogeneity: Tau <sup>2</sup> = 0.40; Ch <sup>2</sup> = 4.15, df = 1 (P = 0.04); l <sup>2</sup> = 76%<br>Tast for overall effect Z = 1.95 (P = 0.05)<br>1.2.2 strong pedro score neuromusular trials<br>Singh 1997 - 1.54 0.44 10 20 3.1% -1.54 [-2.26, -0.82]<br>Prathikant 2017 - 1.08 0.44 15 10 3.1% 1.54 [-2.26, -0.85]<br>Prathikant 2017 - 0.82 0.41 13 13 3.2% -0.82 [-1.49, -0.15]<br>Singh 2005 (1) - 1.88 0.4 18 19 3.3% -1.88 [-2.48, -1.22]<br>Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 - 0.66 1.0.3 27 16 3.7% -0.66 [-1.10, -0.12]<br>Huards 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Huards 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Huards 2012 - 0.06 0.22 42 42 33.5% -1.06 [-1.40, -0.88]<br>Huards 2022 - 0.06 0.22 42 42 43 3.5% -1.06 [-1.40, -0.88]<br>Huards 2022 - 0.06 0.22 42 42 43 3.5% -0.57 [-1.28, -0.22]<br>Fast for overall effect Z = 4.56 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 23%<br>Test for overall effect Z = 4.56 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 9 (P < 0.00001); l <sup>2</sup> = 23%<br>Test for overall effect Z = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 1.44; df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 9 2%<br>Test for overall effect Z = 3.43 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 3.63, df = 11 (P < 0.00001); l <sup>2</sup> = 71%<br>Test for overall effect Z = 3.43 (P = 0.0006)<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 3.63, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect Z = 3.43 (P = 0.0006) | Dovne 1987   | -1.59 0.46                          | 15                       | 11  | 3.0%   | -1.59 [-2.35, -0.83]                       |  |
| Subtal (90% C) 61 57 7.0% -0.99 [-1.83, -0.16]<br>Heterogeneity. $Tat^2 = 0.40; Cht^2 = 4.15, dt = 1 (P = 0.04); P^2 = 76\%$<br>Test for overall effect Z = 1.95 (P = 0.05)<br>1.2.2 strong pedro score neuromuscular trials<br>Singh 1997 - 3.83 0.61 17 19 2.4% -3.83 [-4.83, -2.83]<br>Plu 2007 - 1.54 0.44 10 20 3.1% -1.54 [-2.60, -0.82]<br>Prathikant 2017 - 0.82 0.41 13 13 3.2% -0.82 [-1.49, -0.15]<br>Singh 2005 (1) -1.88 0.4 18 19 3.3% -1.06 [-1.59, -0.41]<br>Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 - 0.61 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Lavretsivg 201 - 1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 - 0.06 0.22 24 2 43 4.0% -0.06 [-0.42, 0.30]<br>Subtatl (90% C) -214 216 335% -1.13 [-2.17, -0.49]<br>Downer 1987 -1.83 0.49 14 11 2.9% -1.38 [-2.64, -1.02]<br>Downer 2015 -0.53; Cht <sup>2</sup> = 4.9.2, dt = 9 (P < 0.00001); I <sup>2</sup> = 82%<br>Test for overall effect Z = 4.56 (P < 0.00001)<br>12.3 weak pedro score endurance trials<br>Carneiro 2015 -0.53; Cht <sup>2</sup> = 4.9.2, dt = 9 (P < 0.00001); I <sup>2</sup> = 82%<br>Test for overall effect Z = -1.34; Cht <sup>2</sup> = 51.44, dt = 4 (P < 0.00001); I <sup>2</sup> = 92%<br>Test for overall effect Z = -1.34; Cht <sup>2</sup> = 51.44, dt = 4 (P < 0.00001); I <sup>2</sup> = 92%<br>Test for overall effect Z = -1.41, 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.42 [-2.42, 0.63]<br>Heterogeneity. Tau <sup>2</sup> = -1.34; Cht <sup>2</sup> = 51.44, dt = 4 (P < 0.00001); I <sup>2</sup> = 92%<br>Test for overall effect Z = 2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Heterogeneity. Tau <sup>2</sup> = -1.34; Cht <sup>2</sup> = 51.44, dt = 4 (P < 0.00001); I <sup>2</sup> = 92%<br>Test for overall effect Z = -2.42 (P = 0.02)<br>12.4 strong pedro score endurance trials<br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Heterogeneity. Tau <sup>2</sup> = -1.34; Cht <sup>2</sup> = -1.44; 2 (P = 0.60)<br>3.42 20 3.5% -0.23 [-0.55], 0.67]<br>Heterogeneity. Tau <sup>2</sup> = -0.21; Cht <sup>2</sup> = -3.80; dt = 11 (P < 0.00001); I <sup>2</sup> = 71%<br>Test for overall effect Z = -3.43 (P = 0.0006)<br>4 4 4 4 2 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4   |  |                                     |                          |     |        |  |  |
| Test for overall effect: $Z = 1.95 (P = 0.05)$<br><b>1.2.2 strong pedro score neuromuscular trials</b><br>Singh 1997 - 1.54 0.61 17 19 2.4% -3.83 [-4.83, -2.83]<br>Plu 2007 - 1.56 0.44 10 20 3.1% -1.54 [-2.6, -0.82]<br>Plu 2007 - 1.68 0.44 113 13 3.2% -0.82 [-1.89, -0.15]<br>Find 2015 (1) - 1.88 0.4 118 19 3.3% -1.08 [-2.54, -1.22]<br>Singh 2005 (2) - 1 0.36 17 19 3.4% -1.00 [-1.59, -0.41]<br>Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.12, -0.13]<br>Huang 2015 - 0.66 1 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Hardrer 2012 - 0.66 0.03 27 16 3.7% -0.61 [-1.10, -0.12]<br>Hardrer 2020 - 0.06 0.22 42 43 4.00% -1.34 [-0.61, -4.7, -0.88]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 (P < 0.00001); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 4.56 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.24 strong pedro score endurance trials</b><br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.24 strong pedro score endurance trials</b><br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.24 strong pedro score endurance trials</b><br>Hemat- Far 2012 - 1.44 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Hegrand 2015 - 0.62 0.32 24 19 3.06% -0.69 (-3.25, 0.67]<br>Tatient pedro score endurance trials<br>Hemat- Far 2012 - 1.44 0.5 10 10 2.8% -1.02 [-1.69, -0.35]<br>Hegrand 2015 - 0.62 0.32 24 19 3.06% -0.63 [-1.25, 0.67]<br>Tatient 2016 - 0.01 0.26 29 28 8.38% -0.01 [-0.44, 0.42]<br>Hemat- Far 2012 - 1.40 0.5 10 10 2.8% -1.23 [-1.79, -0.67]<br>Heterogeneity: Tau <sup>2</sup> = 0.31, Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 71/K<br>Test for overall effect: Z = 3.43 (P = 0.00005)  |  |                                     |                          |     |        |  | <b>•</b>                                   |
| Singh 199 <sup>-</sup><br>- 3.83 0.61 17 19 2.4% -1.83 (-8.3, -2.83)<br>Plu 2007 - 1.54 0.44 10 20 3.1% -1.54 (-2.26, -0.82)<br>Plu 2007 - 0.68 0.41 13 13 3.2% -0.82 (-1.49, -0.15)<br>- 0.72 0.42 0.41 13 13 3.2% -0.82 (-1.49, -0.15)<br>- 0.72 0.42 0.41 13 13 3.2% -0.82 (-1.49, -0.15)<br>- 0.67 0.33 19 20 3.5% -0.67 (-1.21, -0.13)<br>- 0.67 0.33 19 20 3.5% -0.67 (-1.21, -0.13)<br>- 0.67 0.33 19 20 3.5% -0.67 (-1.21, -0.13)<br>- 0.66 0.42 24 43 4.0% -0.06 (-0.42, 0.30)<br>- 0.16 0.02 44 216 33.5% -1.19 (-1.0, -0.12)<br>- 0.16 0.02 44 216 33.5% -1.19 (-1.0, -0.12)<br>- 0.16 0.22 42 43 4.0% -0.06 (-0.42, 0.30)<br>- 0.16 0.02 24 42 43 4.0% -0.06 (-0.42, 0.30)<br>- 0.16 0.22 42 43 4.0% -0.06 (-0.42, 0.30)<br>- 0.16 0.22 42 43 4.0% -0.06 (-0.42, 0.30)<br>- 0.16 0.22 42 43 4.0% -0.05 (-0.42, 0.30)<br>- 0.16 0.22 48 35 4.0% -0.05 (-0.42, 0.30)<br>- 0.08 0.22 48 35 4.0% -0.05 (-0.42, 0.22)<br>- 0.08 0.22 48 35 4.0% -0.05 (-0.22, 1, -2.19)<br>- 0.08 0.22 48 35 4.0% -0.05 (-0.22, 1, -2.19)<br>- 0.08 0.22 48 35 4.0% -0.05 (-0.22, -0.2)<br>- 0.28 (-0.40, 0.28)<br>- 0.29 (-0.40, 0.28)<br>- 0.29 (-0.65, 0.26)<br>- 0.29 (-0.55, 0.67)<br>- 0.29 (-0.55, 0.68)<br>- 0.29 (-0.55, 0.67)<br>- 0.29 (-0.56, 0.06)<br>- 0.21 (-0.40, 0.28)<br>-  |  |                                     | = 76%                    |     |        |  |  |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$   | 1.2.2 strong pedro score neuro                           | muscular trials                     |                          |     |        |  |  |
| Plu 2007 - 1.54 0.44 10 20 3.1% -1.54 [-2.26, -0.82]<br>Prathkani 2017 - 1.08 0.44 15 10 3.1% -1.08 [-1.80, -0.36]<br>Chu 2017 - 0.82 0.41 13 13 3.2% -0.82 [-1.49, -0.15]<br>Singh 2005 (1) -1.88 0.4 18 19 3.3% -1.88 [-2.54, -1.22]<br>Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 -0.61 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Lavretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.00% -0.06 [-0.40, 0.30]<br>Subtoal (90% CI) -1.83 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1967 -1.83 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1967 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Doyne 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>Doyne 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>Doyne 2015 -0.75 0.32 30 16 3.6% -0.76 [-1.24, -0.48]<br>Valter 2000 +124 2113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>12.4 vertice at al. (2011) -0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CI) -142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>12.4 storag pedro score endurance trials<br>Hemat- Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Hegrand 2015 -0.69 0.32 24 19 3.6% -0.03 [-0.44, 0.28]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>12.4 storag pedro score endurance trials<br>Hemat- Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Hegrand 2015 -0.67 0.31 22 20 3.56 * -0.32 [-0.48, 0.47]<br>Heterogeneity: Tau <sup>2</sup> = 0.32 0.31 22 20 3.56 * -0.32 [-0.48, 0.49]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  | Singh 1997   | -3.83 0.61                          | 17                       | 19  | 2.4%   | -3.83 [-4.83, -2.83]                       | <b>.</b>                                   |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$   | Pilu 2007  | -1.54 0.44                          | 10                       | 20  | 3.1%   | -1.54 [-2.26, -0.82]                       |  |
| Singh 2005 (1) -1.88 0.4 18 19 3.3% -1.81 [-2.54, -1.22]<br>Singh 2005 (2) -1 0.36 17 19 3.4% -1.00 [-1.59, -0.41]<br>Huang 2015 -0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 -0.61 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Havretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Subtotal (90% C) 214 216 33.5% -1.19 [-1.61, -0.76]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 ( $P < < 0.00001$ ); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 ( $P < 0.00001$ )<br>12.3 weak pedro score endurance trials<br>Carneiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Do cose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (1992) -0.08 0.22 48 35 4.00.40, 0.28 [-2.40, -0.08]<br>Subtotal (90% C) 142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>12.4 strong pedro score endurance trials<br>Hemat-Far 2015 -1.66 0.48 14 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.8% -1.41 [-2.23, -0.59]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>12.4 strong pedro score endurance trials<br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Heterogeneity: Tau <sup>2</sup> = 0.33; 0.31 22 20 3.5% -0.32 [-6.80, 0.67]<br>Danielsson 2014 -1.23 0.34 22 20 3.5% -0.32 [-6.80, 0.67]<br>Harrisen 1985 -0.69 0.32 24 19 3.6% -0.69 [-1.22, -0.61]<br>HM: Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>HM: Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>HM: Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>HM: Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>HM: Herogeneity: Tau <sup>2</sup> = 0.21; Chl <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 ( $P = 0.00005$   | Prathikanti 2017   | -1.08 0.44                          | 15                       | 10  | 3.1%   | -1.08 [-1.80, -0.36]                       |  |
| Singh 2005 (1) -1.88 0.4 18 19 3.3% -1.88 [-2.54, -1.22]<br>Huang 2015 -0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 -0.61 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Huaretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Subtotal (90% C) 214 216 33.5% -1.19 [-1.61, -0.76]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 ( $P < < 0.00001$ ); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 ( $P < < 0.00001$ )<br>L2.3 weak pedro score endurance trials<br>Carmeiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Do cose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.23, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.66% -2.75 [-1.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 ( $P < < 0.0001$ ); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>12.4 strong pedro score endurance trials<br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.29% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-6.9, -0.35]<br>Patient 2015 -0.67 0.32 2.24 19 3.6% -0.06 [-0.55.067]<br>Danielsson 2014 -1.23 0.34 22 20 3.5% -1.23 [-1.79, -0.67]<br>Martingen 1985 -0.69 0.32 24 19 3.6% -0.32 [-6.85, 0.07]<br>Martingen 1985 -0.69 0.32 24 19 3.6% -0.32 [-0.58, 0.17]<br>Martingen 1985 -0.69 0.32 24 19 3.6% -0.32 [-0.58, 0.17]<br>Martingen 2015 -0.32 0.31 22 20 3.5% -0.32 [-0.85, 0.07]<br>Martingen 2015 -0.32 0.31 22 20 3.5% -0.32 [-0.85, 0.07]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chl <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 ( $P = 0.0006$ )<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chl <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 ( $P = 0.0006$ )  | Chu 2017   | -0.82 0.41                          | 13                       | 13  |        |  |  |
| Singh 2005 (2) -1 0.36 17 19 3.4% -1.00 [-1.59, -0.41]<br>Huang 2015 -0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 -0.61 0.3 27 16 3.7% -0.61 [-1.10, -0.12]<br>Lavretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.24, 0.30]<br>Subtotal (90% CI) 214 216 33.5% -1.19 [-1.61, -0.76]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 ( $P < 0.00001$ ); $i^2 = 82\%$<br>Test for overall effect: Z = 4.56 ( $P < 0.00001$ )<br>12.3 weak pedro score endurance trials<br>Carnetio 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Downe 1987 -1.83 0.54 9 14 11 2.9% -1.83 [-2.64, -1.02]<br>Dose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (1992) -0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CC) -1.44 0.75 10 10 2.8% -1.41 [-2.23, -0.59]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); $i^2 = 92\%$<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>12.4 strong pedro score endurance trials<br>Hemat- Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Hemat-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Theterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); $i^2 = 92\%$<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>12.4 strong pedro score endurance trials<br>Hemat- Far 2012 -0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Hemat- Pereira et al. (2011) -1.02 0.31 22 00 3.5% -0.69 [-0.22, -0.67]<br>Aurtinsen 1985 -0.69 0.32 24 19 3.6% -0.69 [-0.22, -0.67]<br>Murtinsen 1985 -0.69 0.32 24 19 3.6% -0.08 [-0.48, 0.19]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.83, 0.19]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.83, 0.19]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>Humenthal 12007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Humenthal 12007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Humenthal 1209 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Subtotal   | Singh 2005 (1)   | -1.88 0.4                           | 18                       | 19  |        |  |  |
| Huang 2015 - 0.67 0.33 19 20 3.5% -0.67 [-1.21, -0.13]<br>Gangadhar 2013 -0.61 0.3 27 16 3.7% -0.67 [-1.21, -0.13]<br>Havretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Subtotal (90% CI) -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Subtotal (90% CI) -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 (P < 0.00001); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 (P < 0.00001)<br><b>1.23 weak pedro score endurance trials</b><br>Carneiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Do cose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (192) -0.08 0.22 48 35 4.0% -0.08 (-0.44, 0.28]<br>Subtotal (90% CI) -142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.24 strong pedro score endurance trials</b><br>Hemat- Far 2012 -1.41 0.5 10 10 2.9% -1.66 [-2.45, -0.87]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.24 strong pedro score endurance trials</b><br>Hemat- Far 2012 -1.41 0.5 10 10 2.9% -1.66 [-2.45, -0.87]<br>Heterogeneity: Tau <sup>2</sup> = 0.321 22 03 3.5% -1.23 [-1.79, -0.67]<br>Martinsen 1985 -0.69 0.32 24 19 3.6% -0.03 [-1.22, -0.16]<br>Hereogeneity: Tau <sup>3</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)<br>Heterogeneity: Tau <sup>3</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  |  |                                     |                          |     |        |  | _ <b>_</b>                                 |
| $ \begin{array}{c} Gangathar 2013 & -0.61 & 0.3 & 27 & 16 & 3.78 & -0.61 \left[-1.10, -0.12\right] \\ Lavretsky 2011 & -1.31 & 0.26 & 36 & 37 & 3.88 & -0.61 \left[-1.10, -0.12\right] \\ Mather 2002 & -0.06 & 0.22 & 42 & 43 & 4.0% & -0.61 \left[-0.42, 0.30\right] \\ Subtotal (90% CI) & 214 & 216 & 33.58 & -1.19 \left[-1.61, -0.76\right] \\ Heterogeneity: Tau2 = 0.53; Ch2 = 49.92, df = 9 (P < 0.00001); l2 = 82% \\ Test for overall effect: Z = 4.56 (P < 0.00001) \\ \hline 12.3 weak pedro score endurance trials \\ Carnetro 2015 & -1.33 & 0.51 & 9 & 10 & 2.8% & -1.33 \left[-2.17, -0.49\right] \\ Doyne 1987 & -1.83 & 0.49 & 14 & 11 & 2.9% & -1.83 \left[-2.64, -1.02\right] \\ Doyne 1987 & -1.83 & 0.49 & 14 & 11 & 2.9% & -1.83 \left[-2.64, -1.02\right] \\ Dose 2015 & -0.75 & 0.32 & 30 & 16 & 3.6% & -0.75 \left[-1.28, -0.22\right] \\ De la Cerda 2011 & -2.7 & 0.31 & 41 & 41 & 3.6% & -0.76 \left[-1.24, -0.28\right] \\ Subtotal (90% CI) & 142 & 113 & 16.9% & -1.32 \left[-2.22, -0.42\right] \\ Heterogeneity: Tau2 = 1.34; Ch2 = 51.44, df = 4 (P < 0.00001); l2 = 92% \\ Test for overall effect: Z = 2.42 (P = 0.02) \\ \hline 12.4 strong pedro score endurance trials \\ Hemat- Far 2012 & -1.66 & 0.48 & 14 & 10 & 2.9% & -1.66 \left[-2.45, -0.67\right] \\ Matrinsen 2015 & -0.69 & 0.32 & 24 & 19 & 0 & 3.2% & -1.23 \left[-1.79, -0.67\right] \\ Darielsson 2014 & -1.23 & 0.34 & 22 & 20 & 3.6% & -0.32 \left[-0.83, 0.19\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.28 & 26 & 26 & 3.7% & -0.39 \left[-0.83, 0.07\right] \\ With Ho 2014 & -0.39 & 0.23 & 0.2 & 55 & 48 & 4.0\% & 0.23 \left[-0.26, 0.48\right] \\ With Ho 2014 & -0.39 & 0.23 & 0.2 & 55 & 48 & 4.0\% & 0.23 \left[-0.60, 0.60\right] \\ With Ho 2014 & -0.39 & 0.23 & 0.2 & 55 & 48 & 4.0\% & 0.23 \left[-0.60, 0.60\right] \\ With Ho 2014 & -0.39 & 0.23 & 0.2 & 55 & 48 & 4.0\% & 0.23 \left[-0.60, 0.60\right] \\ With Ho 2014 & -0.39 & 0.23 & 0.2$   |  |                                     |                          |     |        |  |  |
| Lavretsky 2011 -1.31 0.26 36 37 3.8% -1.31 [-1.74, -0.88]<br>Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Heterogenely: Tau <sup>2</sup> = 0.53; Ch <sup>2</sup> = 49.92, df = 9 ( $P < 0.00001$ ); $P^2 = 82%$<br>Test for overall effect: Z = 4.56 ( $P < 0.00001$ )<br><b>12.3 weak pedro score endurance trials</b><br>Carneiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Down 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Dolose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (1992) -0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CI) -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, 0.67]<br>Heterogeneliy: Tau <sup>2</sup> = 1.34; Ch <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); $P^2 = 92\%$<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br><b>12.4 strong pedro score endurance trials</b><br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, 0.67]<br>Danielsson 2014 -1.23 0.34 22 20 3.5% -1.23 [-1.79, -0.67]<br>Matrinsen 1985 -0.69 0.32 24 19 3.6% -0.32 [-0.63, 0.19]<br>Hetrogonely: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 0.02 43 7 42 3.9% -0.87 [-1.26, -0.48]<br>With Ho 2014 -0.39 0.28 26 26 3.7% -0.38 [-0.48, 0.19]<br>With Ho 2014 -0.39 0.28 26 26 3.7% -0.87 [-0.26, 0.48]<br>Heterogenely: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); $P^2 = 71\%$<br>Subtotal (90% CI) -0.27 0.2 51 49 40.0% -0.32 [-0.68, 0.07]<br>Heterogeneliy: Tau <sup>2</sup> = 0.21; Ch <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); $P^2 = 71\%$   |  |                                     |                          |     |        |  |  |
| Mather 2002 -0.06 0.22 42 43 4.0% -0.06 [-0.42, 0.30]<br>Subtoal (90% Ct) -1.31 0.51 9 (10 2.8% -1.19 [-1.61, -0.76]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Chl <sup>2</sup> = 49.92, df = 9 ( $P < 0.00001$ ); $P^2 = 82\%$<br>Test for overall effect: $Z = 4.56$ ( $P < 0.00001$ )<br><b>1.2.3 weak pedro score endurance trials</b><br>Carneiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Dose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>Dose 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.66% -0.75 [-1.28, -0.22]<br>Veale et al. (1992) -0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtoal (90% Ct) 142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 ( $P < 0.00001$ ); $P^2 = 92\%$<br>Test for overall effect: $Z = 2.42$ ( $P = 0.02$ )<br><b>1.2.4 strong pedro score endurance trials</b><br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patten 2016 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 -1.23 0.34 22 20 3.6% -0.05 [-1.22, -0.16]<br>Herting 2015 -0.32 0.31 22 20 3.6% -0.32 [-1.26, -0.63]<br>Herting 2015 -0.32 0.31 22 20 3.6% -0.32 [-0.83, 0.19]<br>Wi.H. Ho 2014 -0.39 0.28 26 25 3.7% -0.39 [-0.85, 0.07]<br>Wi.H. Ho 2014 -0.39 0.28 26 25 3.7% -0.39 [-0.85, 0.07]<br>Wi.H. Ho 2014 -0.39 0.28 26 25 3.7% -0.39 [-0.85, 0.07]<br>Wi.H. Ho 2014 -0.39 0.28 26 25 3.7% -0.39 [-0.85, 0.07]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.66]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.23 [-0.10, 0.56]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.23 [-0.10, 0.56]<br>Humenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Humenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Humenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chl <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ); $P^2 = 71\%$<br>Test for overall effect: $Z = 3.43$ ( $P = 0.0006$ )   |  |                                     |                          |     |        |  |  |
| Subtotal (90% CI) 214 216 33.5% -1.19 [-1.61, -0.76]<br>Heterogeneity: Tau <sup>2</sup> = 0.53; Chi <sup>2</sup> = 49.92, df = 9 ( $P < 0.00001$ ); I <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 ( $P < 0.00001$ )<br>1.2.3 weak pedro score endurance trials<br>Carneiro 2015 -1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 -1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Dosse 2015 -0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (1992) -0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CI) -1.02 0.0001); I <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 ( $P = 0.02$ )<br>1.2.4 strong pedro score endurance trials<br>Hemat-Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.65 (-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Paten 2016 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 -1.23 0.34 22 20 3.6% -0.52 [-1.28, -0.67]<br>Martinsen 1985 -0.69 0.32 24 19 3.6% 6.06 [-1.22, -0.16]<br>Kerling 2015 -0.32 0.31 22 20 3.6% -0.32 [-0.33, 0.19]<br>WH. Ho 2014 -0.39 0.28 26 63 3.7% -0.39 [-0.35], 0.77<br>Sigueira 2016 -0.01 0.26 29 28 3.8% -0.01 [-0.44, 0.42]<br>Toni 2015 -0.87 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Humenthal 12007 -0.27 0.2 51 49 4.0% -0.27 [-0.26, 0.48]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.26, -0.48]<br>Humenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.66]<br>Humenthal 1209 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Humenthal 1209 0.21; Chi <sup>2</sup> = 38.05, df = 11 ( $P < 0.0001$ ; I <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 ( $P = 0.0006$ )   |  |                                     |                          |     |        |  |  |
| Heterogeneity: Tau <sup>2</sup> = 0.53; Chi <sup>2</sup> = 49.92, df = 9 (P < 0.00001); l <sup>2</sup> = 82%<br>Test for overall effect: Z = 4.56 (P < 0.00001)<br><b>1.2.3 weak pedro score endurance trials</b><br>Carneiro 2015 - 1.33 0.51 9 10 2.8% -1.33 [-2.17, -0.49]<br>Doyne 1987 - 1.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Dose 2015 - 0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>De la Cerda 2011 - 2.7 0.31 41 41 3.6% -2.70 [-3.21, -2.19]<br>Veale et al. (1992) - 0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CI) - 142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chi <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br><b>1.2.4 strong pedro score endurance trials</b><br>Hemat- Far 2012 - 1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 - 1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) - 1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patten 2016 - 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 - 1.23 0.34 22 20 3.5% -1.23 [-1.29, -0.61]<br>Martinsen 1985 - 0.69 0.32 24 19 3.6% -0.69 [-1.22, -0.16]<br>Kerling 2015 - 0.32 0.31 22 20 3.5% -0.33 [-0.83, 0.19]<br>WH. Ho 2014 - 0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>Sigueta 2016 - 0.01 0.26 29 28 3.7% -0.39 [-0.85, 0.07]<br>Sigueta 2016 - 0.01 0.26 29 28 3.7% -0.39 [-0.87, 0.12]<br>Toni 2015 - 0.87 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  |  | -0.06 0.22                          |                          |     |        |  | ▲  |
| 1.2.3 weak pedro score endurance trials         Carneiro 2015 $-1.33$ $0.51$ 9       10 $2.8\%$ $-1.33$ $[-2.17, -0.49]$ Doyne 1987 $-1.83$ $0.49$ 14       11 $2.9\%$ $-1.83$ $[-2.47, -0.49]$ Dose 2015 $-0.75$ $0.32$ 30       16 $3.6\%$ $-0.75$ $1.22$ , $-0.22]$ De la Cerda 2011 $-2.7$ $0.31$ 41 $41$ $3.6\%$ $-0.75$ $1.22$ , $1.2.19]$ Veale et al. (1992) $-0.08$ $0.22$ $48$ $35$ $4.0\%$ $-0.08$ $-0.22$ $-0.48$ $0.22$ , $-0.42]         Heterogeneity: Tau2 = 1.34; Chl2 = 51.44, df = 4 (P < 0.00001); l2 = 92%       Test for overall effect: Z = 2.42 (P = 0.02)       122       113 16.9\% -1.32 -0.44 0.28\% -1.41 0.5 0.06 0.32 142 113 16.9\% -0.59 142 113 16.9\% -0.59 142 133 1.53 1.65 -0.44 0.75 0.67 142 133 1.53 1.66 -0.44 0.53 0.66 0$  | Heterogeneity: Tau <sup>2</sup> = 0.53; Chi <sup>2</sup> |                                     |                          |     |        |  | •  |
| Carnelro 2015       -1.33       0.51       9       10       2.8%       -1.33       [-2.17, -0.49]         Doyne 1987       -1.83       0.49       14       11       2.9%       -1.88       [-2.64, -1.02]         Dose 2015       -0.75       0.32       30       16       3.6%       -0.75       [-1.28, -0.22]         De la Cerda 2011       -2.7       0.31       41       41       3.6%       -2.70       [-3.21, -2.19]         Veale et al. (1992)       -0.08       0.22       48       35       4.0%       -0.08       [-0.44, 0.28]         Subtotal (90% CI)       -1.41       0.5       10       10       2.8%       -1.41       [-2.23, -0.59]         Heaterogeneity: Tau <sup>2</sup> = 1.34; Chi <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%       Test for overall effect: Z = 2.42 (P = 0.02)         12.4 strong pedro score endurance trials       Hemat- Far 2012       -1.41       0.5       10       2.8%       -1.41 [-2.23, -0.59]         Legrand 2015       -1.66       0.48       14       10       2.9%       -1.06 [-2.45, -0.87]         Patten 2016       0.06       0.37       15       3.4%       0.06 [-0.55, 0.67]         Danielsson 2014       -1.23       0.34       22       20   | Test for overall effect: $Z = 4.56$ (                    | P < 0.00001)                        |                          |     |        |  |  |
| Doyne 19871.83 0.49 14 11 2.9% -1.83 [-2.64, -1.02]<br>Doose 2015 - 0.75 0.32 30 16 3.6% -0.75 [-1.28, -0.22]<br>Veale et al. (1992) - 0.08 0.22 48 35 4.0% -0.08 [-0.44, 0.28]<br>Subtotal (90% CI) + 142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chi <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>1.2.4 strong pedro score endurance trials<br>Hemat- Far 2012 - 1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 - 1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) - 1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patter 2016 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 - 1.23 0.34 22 20 3.5% -0.32 [-0.83, 0.19]<br>Wi-H do 2014 - 0.39 0.28 26 26 3.7% -0.39 [-0.38, 0.07]<br>Kerling 2015 - 0.687 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Wi-H do 2014 - 0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>Siguera 2016 - 0.01 0.26 29 28 3.8% -0.01 [-0.44, 0.42]<br>Toni 2015 - 0.87 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Blumenthal 2007 - 0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 2007 - 0.27 0.2 55 48 4.0% 0.23 [-0.80, 0.07]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  |  | nce trials                          |                          |     |        |  |  |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $   | Carneiro 2015  | -1.33 0.51                          | 9                        | 10  | 2.8%   | -1.33 [-2.17, -0.49]                       | <b>.</b>                                   |
| De la Cerda 2011 -2.7 0.31 41 41 3.6% -2.70 $[-3.21, -2.19]$<br>Veale et al. (1992) -0.08 0.22 48 35 4.0% -0.08 $[-0.44, 0.28]$<br>Subtotal (90% CI) 142 113 16.9% -1.32 $[-2.22, -0.42]$<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>1.2.4 strong pedro score endurance trials<br>Hemat- Far 2012 -1.41 0.5 10 10 2.8% -1.41 $[-2.23, -0.59]$<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 $[-2.45, -0.87]$<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 $[-1.69, -0.35]$<br>Patten 2016 0.06 0.37 15 15 3.4% 0.06 $[-0.55, 0.67]$<br>Danielsson 2014 -1.23 0.34 22 20 3.5% -1.23 $[-1.79, -0.67]$<br>Herling 2015 -0.32 0.31 22 20 3.6% -0.32 $[-0.83, 0.19]$<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 $[-0.85, 0.07]$<br>Siguera 2015 -0.67 0.24 37 42 3.9% -0.08 $[-0.44, 0.42]$<br>For in 2015 -0.27 0.2 51 49 4.0% -0.27 $[-0.60, 0.06]$<br>Blumenthal 2007 -0.27 0.2 51 49 4.0% -0.27 $[-0.60, 0.06]$<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 $[-0.10, 0.56]$<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chl <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)   | Doyne 1987   | -1.83 0.49                          | 14                       | 11  | 2.9%   | -1.83 [-2.64, -1.02]                       | <b>.</b>                                   |
| Veale et al. (1992) $-0.08$ $0.22$ 48       35 $4.0\%$ $-0.08$ $-0.44$ $0.28$ Subtotal (90% CI)       142       113       16.9% $-1.32$ $[-2.22, -0.42]$ Heterogeneity: Tau <sup>2</sup> = 1.34; Chl <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%       Test for overall effect: Z = 2.42 (P = 0.02)         12.4 strong pedro score endurance trials       Hemat- Far 2012 $-1.41$ $0.5$ 10 $10$ $2.8\%$ $-1.41$ $[-2.23, -0.59]$ Legrand 2015 $-1.66$ $0.48$ 14 $0.2.9\%$ $-1.66$ $-0.68$ $-0.69$ $-0.32$ $-0.69$ $-0.32$ $-0.67$ $-0.67$ $-0.67$ $-0.67$ $-0.69$ $-0.32$ $-0.31$ $-0.22$ $-0.56$ $-0.75$ $-0.67$ $-0.69$ $-0.32$ $-0.31$ $-22$ $0.3.6\%$ $-0.69$ $-0.32$ $0.31$ $22$ $20$ $3.5\%$ $-0.69$ $-0.32$ $0.31$ $22$ $20$ $3.6\%$ $-0.69$ $-0.32$ $0.31$ $22$ $20$ $3.6\%$ $-0.69$ $-0.32$ $0.31$ $22$ $20$ $3.6\%$ $-0.69$ $-0.32$ <td< td=""><td>Doose 2015</td><td>-0.75 0.32</td><td>30</td><td>16</td><td>3.6%</td><td>-0.75 [-1.28, -0.22]</td><td></td></td<>   | Doose 2015   | -0.75 0.32                          | 30                       | 16  | 3.6%   | -0.75 [-1.28, -0.22]                       |  |
| Subtotal (90% CI)       142       113       16.9% $-1.32$ [ $-2.22$ , $-0.42$ ]         Heterogeneity: Tau <sup>2</sup> = 1.34; Chi <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%       Test for overall effect: Z = 2.42 (P = 0.02)         12.4 strong pedro score endurance trials       Hemat- Far 2012 $-1.41$ 0.5       10       2.8% $-1.41$ [ $-2.23$ , $-0.59$ ]         Legrand 2015 $-1.66$ 0.48       14       10       2.9% $-1.66$ [ $-2.45$ , $-0.87$ ]         Mota-Pereira et al. (2011) $-1.02$ 0.41       19       10       3.2% $-1.23$ [ $-1.79$ , $-0.67$ ]         Patten 2016       0.06       0.37       15       15       3.4%       0.06 [ $-0.55$ , 0.67]         Danielsson 2014 $-1.23$ 0.34       22       20       3.5% $-0.32$ [ $-0.83$ , 0.19]         W.H. Ho 2014 $-0.39$ 0.28       26       26 $3.7\%$ $-0.39$ [ $-0.85$ , 0.07]         Siqueira 2016 $-0.01$ 0.26       29       28 $3.8\%$ $-0.01$ [ $-0.44$ , 0.42]         W.H. Ho 2014 $-0.39$ 0.23       0.2       55       48 $-0.87$ [ $-0.66$ , 0.06] $-0.87$ [ $-0.67$ ]         Blumenthal 2007 $-0.27$ 0.2       51       49  | De la Cerda 2011   | -2.7 0.31                           | 41                       | 41  | 3.6%   | -2.70 [-3.21, -2.19]                       | _ <b>_</b>                                 |
| Subtotal (90% CI) 142 113 16.9% -1.32 [-2.22, -0.42]<br>Heterogeneity: Tau <sup>2</sup> = 1.34; Chi <sup>2</sup> = 51.44, df = 4 (P < 0.00001); l <sup>2</sup> = 92%<br>Test for overall effect: Z = 2.42 (P = 0.02)<br>1.2.4 strong pedro score endurance trials<br>Hemat- Far 2012 -1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patten 2016 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Patten 2016 0.06 0.33 22 20 3.5% -1.23 [-1.79, -0.67]<br>Martinsen 1985 -0.69 0.32 24 19 3.6% -0.69 [-1.22, -0.16]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.83, 0.07]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.83, 0.07]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.65, 0.67]<br>Joni 2015 -0.32 0.31 22 29 3.6% -0.01 [-0.44, 0.42]<br>Toni 2015 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 2007 -0.27 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Blumenthal 2007 -0.27 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Blumenthal 2007 -0.27 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Blumenthal 2007 -0.27 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)   | Veale et al. (1992)                                      | -0.08 0.22                          | 48                       | 35  |        |  |  |
| Test for overall effect: $Z = 2.42$ (P = 0.02)<br>1.2.4 strong pedro score endurance trials<br>Hemat- Far 2012 - 1.41 0.5 10 10 2.8% -1.41 [-2.23, -0.59]<br>Legrand 2015 - 1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patten 2016 0.06 0.37 15 15 3.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 - 1.23 0.34 22 20 3.5% -1.23 [-1.79, -0.67]<br>Martinsen 1985 -0.69 0.32 24 19 3.6% -0.69 [-1.22, -0.16]<br>Kerling 2015 -0.32 0.31 22 20 3.6% -0.32 [-0.83, 0.19]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>Sigueira 2016 -0.01 0.26 29 28 3.8% -0.01 [-0.44, 0.42]<br>Toni 2015 -0.87 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Blumenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Subtotal (90% CI) 324 29 -0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  | Subtotal (90% CI)  |                                     | 142                      | 113 | 16.9%  | -1.32 [-2.22, -0.42]                       | ◆  |
| Hemat- Far 2012-1.410.510102.8%-1.41[-2.23, -0.59]Legrand 2015-1.660.4814102.9%-1.66[-2.45, -0.87]Mota-Pereira et al. (2011)-1.020.4119103.2%-1.02[-1.69, -0.35]Patten 20160.060.3715153.4%0.06[-0.55, 0.67]Danielsson 2014-1.230.3422203.5%-1.23[-1.79, -0.67]Martinsen 1985-0.690.3224193.6%-0.69[-1.22, -0.16]W.H. Ho 2014-0.390.2826263.7%-0.39[-0.83, 0.07]Siqueira 2016-0.010.2629283.8%-0.01[-0.44, 0.42]Toni 2015-0.870.2437423.9%-0.87[-1.64, -0.48]Blumenthal 2007-0.270.251494.0%-0.27[-0.60, 0.06]Blumenthal 10970.230.255484.0%-0.25[-0.82, -0.29]Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%Test for overall effect: Z = 3.43 (P = 0.0006)  |  |                                     | 1); I <sup>2</sup> = 92% |     |        |  |  |
| Legrand 2015 -1.66 0.48 14 10 2.9% -1.66 [-2.45, -0.87]<br>Mota-Pereira et al. (2011) -1.02 0.41 19 10 3.2% -1.02 [-1.69, -0.35]<br>Patten 2016 0.06 0.37 15 13.4% 0.06 [-0.55, 0.67]<br>Danielsson 2014 -1.23 0.34 22 20 3.5% -1.23 [-1.79, -0.67]<br>Martinsen 1985 -0.69 0.32 24 19 3.6% -0.69 [-1.22, -0.16]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.83, 0.19]<br>W.H. Ho 2014 -0.39 0.28 26 26 3.7% -0.39 [-0.85, 0.07]<br>Siqueira 2016 -0.01 0.26 29 28 3.8% -0.01 [-0.44, 0.42]<br>Toni 2015 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Subtotal (0% CI) -324 297 42.6% -0.55 [-0.82, -0.29]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  | 1.2.4 strong pedro score endur                           | ance trials                         |                          |     |        |  |  |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $  | Hemat- Far 2012  | -1.41 0.5                           | 10                       | 10  | 2.8%   | -1.41 [-2.23, -0.59]                       | <b>_</b> _                                 |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $  | Legrand 2015   | -1.66 0.48                          | 14                       | 10  | 2.9%   | -1.66 [-2.45, -0.87]                       |  |
| Patten 2016       0.06       0.37       15       15       3.4%       0.06 [-0.55, 0.67]         Danielsson 2014       -1.23       0.34       22       20       3.5%       -1.23 [-1.79, -0.67]         Martinsen 1985       -0.69       0.32       24       19       3.6%       -0.69 [-1.22, -0.16]         Kerling 2015       -0.32       0.31       22       20       3.6%       -0.32 [-0.83, 0.19]         W.H. Ho 2014       -0.39       0.28       26       26       3.7%       -0.03 [-0.45, 0.07]         Siqueira 2016       -0.01       0.26       29       28       3.8%       -0.06 [-1.26, -0.48]         Toni 2015       -0.87       0.24       37       42       3.9%       -0.07 [-0.46, 0.42]         Blumenthal 2007       -0.27       0.2       51       49       4.0%       -0.27 [-0.60, 0.06]         Blumenthal 1999       0.23       0.2       55       4.0%       0.023 [-0.10, 0.56]       42.6%         Subtotal (90% CI)       324       297       42.6%       -0.55 [-0.82, -0.29]       42.6%         Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%       Test for overall effect: Z = 3.43 (P = 0.0006)       42.6%       -0.55 [-0.82, -0.29]       42.6%  | Mota-Pereira et al. (2011)                               | -1.02 0.41                          | 19                       | 10  | 3.2%   | -1.02 [-1.69, -0.35]                       | <b>_</b> _                                 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $   |  |                                     | 15                       |     |        |  |  |
| Martinsen 1985 $-0.69$ $0.32$ $24$ $19$ $3.6\%$ $-0.69$ $[-1.22, -0.16]$ Kerling 2015 $-0.32$ $0.31$ $22$ $20$ $3.6\%$ $-0.32$ $[-0.38, 0.19]$ WH. Ho 2014 $-0.39$ $0.28$ $26$ $26$ $3.7\%$ $-0.32$ $[-0.38, 0.07]$ Siqueria 2016 $-0.01$ $0.26$ $29$ $28$ $8.\%$ $-0.01$ $[-0.44, 0.42]$ Toni 2015 $-0.87$ $0.24$ $37$ $42$ $3.9\%$ $-0.87$ $[-1.26, -0.48]$ Blumenthal 2007 $-0.27$ $0.27$ $55$ $48$ $4.0\%$ $0.23$ $[-0.40, 0.56]$ Subtotal (90% CI) $324$ $297$ $42.6\%$ $-0.55$ $[-0.82, -0.29]$ Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); I <sup>2</sup> = 71\% $72\%$ $72\%$ $72\%$ $72\%$ Test for overall effect: Z = 3.43 (P = 0.0006) $40.00001$ ; I <sup>2</sup> = 71\% $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ $72\%$ <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>_<b>_</b></td></th<>  |  |                                     |                          |     |        |  | _ <b>_</b>                                 |
| Kerling 2015 $-0.32$ $0.31$ $22$ $20$ $3.6\%$ $-0.32$ $(-0.83, 0.19)$ W.H. Ho 2014 $-0.39$ $0.28$ $26$ $26$ $3.7\%$ $-0.39$ $(-0.83, 0.07)$ Siqueira 2016 $-0.01$ $0.26$ $29$ $28$ $3.8\%$ $-0.01$ $(-0.44, 0.42)$ Toni 2015 $-0.87$ $0.24$ $37$ $42$ $3.9\%$ $-0.87$ $(-1.26, -0.48)$ Blumenthal 2007 $-0.27$ $0.2$ $51$ $49$ $4.0\%$ $-0.27$ $(-0.60, 0.06)$ Blumenthal 1999 $0.23$ $0.2$ $55$ $48$ $4.0\%$ $0.23$ $(-0.10, 0.56)$ Subtotal (90% CI) $324$ $297$ $42.6\%$ $-0.55$ $(-0.82, -0.29)$ Heterogeneity: Tau <sup>2</sup> = $0.21$ ; Chi <sup>2</sup> = $38.05$ , df = $11$ (P < $0.0001$ ); i <sup>2</sup> = $71\%$ Test for overall effect: Z = $3.43$ (P = $0.0006$ ) $-0.0001$ ; i <sup>2</sup> = $71\%$  |  |                                     |                          |     |        |  |  |
| W.H. $lo 2014$ -0.39       0.28       26       26       3.7%       -0.39       [-0.85, 0.07]         Siqueira 2016       -0.01       0.26       29       28       3.8%       -0.01[-0.44, 0.42]         Toni 2015       -0.87       0.24       37       42       3.9%       -0.87 [-1.26, -0.48]         Blumenthal 2007       -0.27       0.2       51       49       4.0%       -0.27 [-0.60, 0.06]         Subtotal (90% CI)       324       297       42.6%       -0.55 [-0.82, -0.29]       +         Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%       Test for overall effect: Z = 3.43 (P = 0.0006)       +       +   |  |                                     |                          |     |        |  |  |
| Siqueira 2016 $-0.01$ $0.26$ $29$ $28$ $3.8\%$ $-0.01$ $0.42$ Toni 2015 $-0.87$ $0.24$ $37$ $42$ $3.9\%$ $-0.87$ $1.26$ , $-0.48$ Blumenthal 2007 $-0.27$ $0.2$ $51$ $49$ $4.0\%$ $-0.27$ $-0.27$ $0.2$ $51$ $49$ $4.0\%$ $-0.27$ $-0.27$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.27$ $0.27$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.23$ $0.25$ $0.25$ $0.25$ $0.25$ $0.25$ $0.23$ <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>_<b>_</b></td></td<>   |  |                                     |                          |     |        |  | _ <b>_</b>                                 |
| Toni 2015 -0.87 0.24 37 42 3.9% -0.87 [-1.26, -0.48]<br>Blumenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 1999 0.23 0.2 25 48 4.0% -0.23 [-0.10, 0.56]<br>Subtotal (90% Cl) 324 297 42.6% -0.55 [-0.82, -0.29]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); i <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  |  |                                     |                          |     |        |  |  |
| Blumenthal 2007 -0.27 0.2 51 49 4.0% -0.27 [-0.60, 0.06]<br>Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Subtotal (90% CI) 324 297 42.6% -0.55 [-0.82, -0.29]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)   |  |                                     |                          |     |        |  | -  |
| Blumenthal 1999 0.23 0.2 55 48 4.0% 0.23 [-0.10, 0.56]<br>Subtotal (90% Cl) 324 297 42.6% -0.55 [-0.82, -0.29]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); $I^2$ = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)  |  |                                     |                          |     |        |  |  |
| Subtotal (90% Cl) 324 297 42.6% -0.55 [-0.82, -0.29]<br>Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)   |  |                                     |                          |     |        |  | -  |
| Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> = 38.05, df = 11 (P < 0.0001); l <sup>2</sup> = 71%<br>Test for overall effect: Z = 3.43 (P = 0.0006)   |  | 0.25 0.2                            |                          |     |        |  | •  |
| Total (90% CI) 741 683 100.0% -0.93 [-1.17, -0.70]   | Heterogeneity: Tau <sup>2</sup> = 0.21; Chi <sup>2</sup> |                                     | 1); $I^2 = 71\%$         |     |        |  | •  |
|  | Total (90% CI)   |                                     | 741                      | 683 | 100.0% | -0.93 [-1.17, -0.70]                       | •  |
| Heterogeneity: Tau <sup>2</sup> = 0.46; Chl <sup>2</sup> = 164.60, df = 28 (P < 0.00001); l <sup>2</sup> = 83%   | Heterogeneity: Tau <sup>2</sup> = 0.46; Chi <sup>2</sup> | = 164.60, df = 28 (P < 0.00)        | $001$ ; $I^2 = 83$       | 3%  |        |  |  |
| Test for overall effect: Z = 6.55 (P < 0.00001) Favours [experimental] Favours [control]   | Test for overall effect: Z = 6.55 (                      | P < 0.00001)                        |                          |     |        |  |  |
| Test for subgroup differences: Chi <sup>2</sup> = 5.58, df = 3 (P = 0.13), i <sup>2</sup> = 46.2%  | Test for subgroup differences: Ch                        | $i^2 = 5.58$ , df = 3 (P = 0.13), I | $^{2} = 46.2\%$          |     |        |  | ravous (experimental) ravous (control)     |

independent variable.

good if a study fulfilled the criteria of an adequate allocation concealment, the use of intention-to-treat analysis and blinded outcome assessment. Since they had only two trials fulfilling these criteria, the result of g = -0.43 should be regarded with caution. There was only one available meta-analysis (10) with contrary results on the link between methodological issues and effect sizes. Rethorst et al. (10) found an overall effect size of g = -0.80 (95% CI: -0.92 to 0.67) and they noted that studies using intention-to-treat analysis and adequate allocation concealment achieve larger effect sizes. Further meta-analyses revealed only moderate effect sizes, such as Silveira et al. (58) with g = -0.61 (95% CI: -0.88 to -0.33) and (59) with g =-0.68 (95% CI: -0.92 to -0.44) compared to large effect sizes in our meta-analyses. However, their findings might be biased toward an underrated effect in both meta-analyses due to the number of included studies with an inappropriate, active control group [for example (22)] performing low- intensity exercise. Previous studies suggested that also low-intensity exercise has a meaningful effect on depressive symptoms and cognitive variables (60, 61) in patients suffering from depression. Thus, we conclude the inappropriate control group as a reason for the bigger effect sizes in favor of exercise in our meta-analysis compared to earlier meta-analyses. Further meta-analysis and researches should also exclude studies with active control groups, irrespective of the exercise intensity in the control group.

### Comparing of Endurance and Neuromuscular Exercise Interventions

Our sensitivity analysis differentiating the endurance and neuromuscular exercise intervention effects resulted in a meaningful difference of effect size when considering strong studies based on PEDro score evaluation. Thus, we conclude that neuromuscular exercise interventions can be more effective than endurance exercise interventions in the treatment of depression. Allocation of patients either to endurance or neuromuscular exercise training programs could be conducted based on individual preferences, emphasizing the potential of strength

 $\label{eq:table_table_table_table} \textbf{TABLE 5} \mid \textbf{Multivariate meta-regression analysis results in endurance interventions.}$ 

| Moderator            | Estimate | Standard error | р    | 95 %-CI      |
|----------------------|----------|----------------|------|--------------|
| Intercept            | 2.46     | 2.82           | 0.38 | -3.07; 7.99  |
| Duration of sessions | -0.06    | 0.02           | 0.01 | -0.11; -0.01 |
| Frequency            | -0.24    | 0.18           | 0.18 | -0.60; 0.12  |
| Intensity            | 0.01     | 0.02           | 0.81 | -0.04; 0.05  |
| Number of sessions   | 0.01     | 0.01           | 0.50 | -0.01; 0.02  |
|                      |          |                |      |              |

 TABLE 6 | Multivariate meta-regression analysis results in neuromuscular interventions.

| Moderator            | Estimate | Standard error | р    | 95 %-CI      |
|----------------------|----------|----------------|------|--------------|
| Intercept            | 3.133    | 1.999          | 0.12 | -0.78; 7.05  |
| Duration of sessions | -0.009   | 0.011          | 0.44 | -0.03; 0.01  |
| Frequency            | 0.002    | 0.171          | 0.99 | -0.33; 0.34  |
| Intensity            | -0.054   | 0.028          | 0.05 | -0.11; -0.00 |
| Number of sessions   | -0.017   | 0.02           | 0.38 | -0.06; 0.02  |
|                      |          |                |      |              |

training. The comparison of our results with earlier metaanalyses is however quite difficult. One available meta-analysis of Silveira et al. (58) is supporting our assumption. They found an effect size of g = -0.96 (95% CI: -1.97 to 0.05) for strength exercise interventions and an effect size of g = -0.52 (95% CI: -0.79 to -0.25) for endurance interventions. The effect size is underestimated in both groups because of the inclusion of Krogh et al. (22) showing no effects in favor of any exercise interventions.

In contrast, Rethorst et al. (10) did not support the assumption as they could not find a difference between aerobic and strength exercise. Continuing sensitivity analysis showed that combined aerobic and strength exercise interventions resulted in larger effects. As a consequence, they recommended mixed exercise activities in the treatment of depression. This contrasts with (20) who noted that only aerobic exercise has a large effect on depression, but mixed exercise interventions and resistance exercise interventions have no significant effects. Because of a small number of included studies reporting resistance training in the treatment of depression, their conclusion should be interpreted with caution.

### Training Parameters Moderate the Antidepressant Effect of Exercise Interventions

We found significant moderating effects for the training prescriptors "exercise duration" in the way that an extended exercise duration strengthened the antidepressant effect of endurance exercise interventions. We found an antidepressant effect size increase of -0.62 for exercising 10 min longer. Furthermore, we found significant results for the training prescriptor "exercise intensity" in the way that an increased exercise intensity strengthened the antidepressant effect of neuromuscular exercise interventions. Furthermore, we found an

effect size increase of -0.54 in favor of neuromuscular exercise for a 10% increase of exercise intensity. Based on these findings, we cautiously suggest that high intensity neuromuscular exercise can be more effective than low intensity neuromuscular exercise in the treatment of depression. Nevertheless, this conclusion is debatable because of different descriptions of the exercise intensity used in the included neuromuscular intervention trials.

Previous meta-analyses revealed different results in their analyses. Silveira et al. (58) stated that "training parameters such as frequency, intervention period, intensity and duration of training (...) do not exert any influence on the response to treatment" (p. xxx). But they also noted, that the training parameters of most of the included studies were similar concerning to exercise duration, frequency and intensity. However, meta-regression has not been computed in their study.

Another meta-analysis (20) supports our assumption that exercise intensity moderates the antidepressant effect of exercise interventions. They found that moderate to vigorous exercise intensity is more effective than light to moderate exercise intensity. This finding slightly contrasts with (10) who did not find a dose-response relationship between exercise intensity and depression scores in clinically depressed patients. However, they did not differentiate between neuromuscular and endurance exercise. Therefore, a comparison with our results is difficult. Rethorst et al. (10) further found that an exercise duration of 45–49 min results in larger effects than an exercise duration of <45 min or higher than 60 min. These finding supports our conclusion to some extent that longer exercise duration leads to larger effects regarding endurance training.

### **Strengths and Limitations**

The present meta-analytical review was conducted according to the PRISMA statement (25) and along the PICOS approach (27). Our overall sample size of n = 1,452 in 27 included trials is presumed to be good and one of the biggest meta-analysis examining the antidepressant effect of exercise interventions. Sensitivity analyses were conducted to differentiate between endurance and neuromuscular exercise interventions as well as between studies with higher and lower quality. The overall mean of the study quality (PEDro score) including all endurance and neuromuscular intervention trials was 6.4 and methodological quality can be assumed to be sound.

The calculated effect sizes were accompanied with a large heterogeneity between the included studies and reasonably narrow confidence intervals. Therefore, our findings provide a comprehensive view of the differential effects of endurance vs. neuromuscular exercise interventions in the treatment of depression.

However, depressive disorders can encompass a plenty of different signs and symptoms which could be also in contrast to each other (DSM-5) such as decreased mood tone, apathy, emotional blunting, hypersomnia, lack of energy, anhedonia, but also irritability, anxiety, hyperphagia, insomnia, and motor activation. A major depressed patient with a melancholic pattern characterized by a marked energy impairment is not likely to benefit from physical exercises more than antidepressant drug administration. Thus, exercise should only be administered as a complementary treatment therapy and not as a substitute for pharmaceutical therapy. In line with this point, a lack of patients' stratification according to severity of symptoms of the underlying studies might provoke a selection bias, as a patient with a high score at HAMD could be less prone to undergo physical exercise in comparison with a patient with less severe depressive symptoms. Moreover, selected studies had to provide adult patients who met criteria for depressive disorder according to DSM IV (validated by SCID), ICD-10, or RDC. On the other hand, BDI-II, GDS, and PHQ-9 are currently used to assess the severity of depressive symptoms, but they are not diagnostic scales. Thus, subgroup analyses on severity of depression and exercise effect was not calculable due to the small resulting sample and used scales. The majority of the included trials show clinical difference between severe, moderate and mild depressions which provoke a lack of stratification which can be clinically relevant too and could be a possible bias. Finally, the control groups have practiced other therapies, also pharmacotherapy, this is a considerable bias with lack of stratification.

Our findings on the influence of different exercise training prescriptors might be biased because of the inclusion of the weaker studies in the analysis. A meta-regression analysis only including the studies with sound methodological quality could lead to different conclusions. Also, the different exercise intensity descriptions in the trials and our transformation to percentage groups to enable adequate comparison may create a limitation to our meta-regression analysis. Further, the blinding of therapist, subject and assessor is impossible in exercise intervention and this may introduce bias. There are also several studies that compared combined exercise and medication treatment to only antidepressant medication treatment. The impact of the antidepressant medication treatment in these studies is unknown and therefore, we do not know how big this potential limitation for our meta-analysis might be.

### REFERENCES

- 1. WHO. *Depression (fact sheet, nr 369)*. (2017). Available online at: http://www. who.int/mediacentre/factsheets/fs369/en/ (Accessed December 06, 2017).
- Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. *Lancet* (2006) 367:153–67. doi: 10.1016/S0140-6736(06)67964-6
- 3. Halliwell E, Richardson C, McCulloch A, Ryrie I. *Up and Running?: Exercise Therapy and the Treatment of Mild or Moderate Depression in Primary care.* Mental Health Foundation (2005).
- Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* (2009) 373:746– 58. doi: 10.1016/S0140-6736(09)60046-5
- Trindade E., Menon D., Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. *Cmaj* (1998) 159:1245–52.
- Berken GH, Weinstein DO, Stern WC. Weight gain. A sideeffect of tricyclic antidepressants (1984) J Affect Disord. 7:133–8. doi: 10.1016/0165-0327(84)90031-4

### CONCLUSION

Our meta-analysis underpins that exercise training is generally an effective complementary treatment option for depressed patients. Interestingly, neuromuscular exercise interventions can be more effective than endurance exercise interventions when only considering stronger trials. This finding underpins the need of allocating patients to neuromuscular training based on scientific evidence and individual preferences, goals and barriers. To confirm this finding, further randomized controlled trials with clear defined strength training interventions are required. To strengthen our findings regarding the moderation of exercise duration in endurance interventions and exercise intensity in neuromuscular interventions, concurrent training parameters in prospective randomized controlled trials are needed.

Overall, further randomized controlled trials of exercise interventions following the PICOS approach and clearly defined training parameters are required, especially with severely depressed patients in order to state more on the potential of neuromuscular and endurance training in patients that might be less prone to complementary exercise-based treatments. However, strength and endurance training with longer duration and intensities, respectively, should be progressively embedded into treatment regimen of depressed patients.

### **AUTHOR CONTRIBUTIONS**

LN and LD wrote the whole review of abstract, introduction, material and methods, results, discussion and made tables and figures. LN and LD did study selection and discussed data extraction. LN and EL did methodological quality assessment and statistical analysis. OF and LZ gave comments and advices. AM and MG gave comments and advices to the final version of the manuscript. All authors approved the final version for submission.

- Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. *Int J Psychiatry Med.* (1995) 25:191– 201. doi: 10.2190/1DHU-Y7L7-9GKG-V7WV
- WHO. *Mental Health. Physical Activity*. (n.d.). Available online at: http:// www.who.int/mental\_health/mhgap/evidence/depression/q6/en/ (Accessed December 06, 2017).
- 9. NICE Depression: The Treatmentand Management of Depressionin Adults. NICE Clinical Guidelhine 90 (2013).
- Rethorst CD, Wipfli BM, Landers DM. The antidepressive effects of exercise: a meta-analysis of randomized trials. *Sports Med.* (2009) 39:491–511. doi: 10.2165/00007256-200939060-00004
- 11. Biddle SH, Mutrie, N. (2008). *The Psychology of Physical Activity*. London: Routledge.
- Roston WL, Whipp BJ, Davis JA, Cunningham DA, Effros RM, Wasserman K. Oxygen uptake kinetics and lactate concentration during exercise in humans. *Am Rev Respir Dis.* (1987) 135:1080–4.
- Stubbs B, Rosenbaum S, Vancampfort D, Ward PB, Schuch FB. Exercise improves cardiorespiratory fitness in people with depression: a metaanalysis of randomized control trials. J Affect Disord. (2016) 190:249–53. doi: 10.1016/j.jad.2015.10.010

- Bridle C, Spanjers K, Patel S, Atherton NM, Lamb SE. Effect of exercise on depression severity in older people: systematic review and metaanalysis of randomised controlled trials. *Br J Psychiatry* (2012) 201:180–5. doi: 10.1192/bjp.bp.111.095174
- Krogh J, Nordentoft M, Sterne JA, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. *J Clin Psychiatry* (2011) 72:529–38. doi: 10.4088/JCP.08r04913blu
- Josefsson T, Lindwall M, Archer, T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. *Scand J Med Sci Sports* (2014) 24:259–72. doi: 10.1111/sms.12050
- Craft L, Landers, M. The effect of exercise on clinical depression and depression resulting from mental illness: a meta-analysis. J Sport Exerc Psychol. (1998) 20:339–57. doi: 10.1123/jsep.20.4.339
- Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. *Coch Database Syst Rev.* (2009) 3:Cd004366. doi: 10.1002/14651858.CD004366.pub4
- Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and metaregression analysis of randomised controlled trials. *BMJ* (2001) 322:763. doi: 10.1136/bmj.322.7289.763
- Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. (2016) 77:42–51. doi: 10.1016/j.jpsychires.2016.02.023
- Stathopoulou G, Powers M, Berry AC, Smits J, Otto W. Exercise interventions for mental health: a quantitative and qualitative review. *Clin. Psychol.* (2006) 13:179–93. doi: 10.1111/j.1468-2850.2006.00021.x
- Krogh J, Saltin B, Gluud C, Nordentoft, M. The DEMO trial: a randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate depression. J Clin Psychiatry (2009) 70:790–800. doi: 10.4088/JCP.08m04241
- Schulz K, Chalmers FI, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials *JAMA* (1995) 273:408–12. doi: 10.1001/jama.1995.03520290060030
- Hawley JA. Molecular responses to strength and endurance training: are they incompatible? *Appl Physiol Nutr Metab.* (2009) 34:355–361. doi: 10.1139/H09-023
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med.* (2015) 162:777–84. doi: 10.7326/M14-2385
- Schuch FB, Morres ID, Ekkekakis P, Rosenbaum S, Stubbs, B. A critical review of exercise as a treatment for clinically depressed adults: time to get pragmatic. *Acta Neuropsychiatr.* (2017) 29:65–71. doi: 10.1017/neu.2016.21
- 27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. (2009) 62:e1–34. doi: 10.1016/j.jclinepi.2009.06.006
- Kerling A, Tegtbur U, Gützlaff E, Kück M, Borchert L, Ates Z, et al. Effects of adjunctive exercise on physiological and psychological parameters in depression: a randomized pilot trial. J Affect Disord. (2015) 177:1–6. doi: 10.1016/j.jad.2015.01.006
- Doyne EJ, Ossip-Klein DJ, Bowman ED, Osborn KM, McDougall-Wilson IB, Neimeyer, R. A. Running versus weight lifting in the treatment of depression. *J Consult Clin Psychol.* (1987) 55:748–54.
- Chu I, Hua W-L, Wu I, Mei L, Yu-Kai C, Yuh-Jen L, Pin-Chen Y. (2017). Effects of Yoga on Heart Rate Variability and Depressive Symptoms in Women: A Randomized Controlled Trial. J Altern Comp Med. 23, 310–6. doi: 10.1089/acm.2016.0135
- Field T, Diego M, Delgado L, Medina, L. Tai chi/yoga reduces prenatal depression, anxiety and sleep disturbances. *Compl Ther Clin Pract.* (2013) 19:6–10. doi: 10.1016/j.ctcp.2012.10.001
- Gangadhar BN, Naveen GH., Rao MG, Thirthalli J, Varambally, S. Positive antidepressant effects of generic yoga in depressive outpatients, a comparative study. *Indian J Psychiatry* (2013) 55:S369–73. doi: 10.4103/0019-5545.116312

- 33. Huang TT, Liu CB, Tsai YH, Chin YF, Wong CH. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-dwelling elderly adults: a randomized controlled trial. *Int J Nurs Stud.* (2015) 52:1542–52. doi: 10.1016/j.ijnurstu.2015.05.013
- Lavretsky H, Alstein L, Olmstead RE, Ercoli LM, Riparetti-Brown M, Cyr NS, et al. Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. *Am J Geriatr Psychiatry* (2011) 19:839–50. doi: 10.1097/JGP.0b013e31820ee9ef
- Mather A, Rodriguez C, Guthrie M, McHarg A, Reid I, McMurdo, M. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder. *Br J Psychiatry* (2002) 180:411–5. doi: 10.1192/bjp.180.5.411
- Pilu A, Sorba M, Hardoy MC, Floris AL, Mannu F, Seruis ML, et al. Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results. *Clin Pract Epidemiol Ment Health* (2007) 3:8. doi: 10.1186/1745-0179-3-8
- Prathikanti S, Rivera R, Cochran A, Tungol JG, Fayazmanesh N, Weinmann, E. Treating major depression with yoga: a prospective, randomized, controlled pilot trial. *PLoS ONE* (2017) 12:e0173869. doi: 10.1371/journal.pone.0173869
- Singh N, Clements K, Fiatarone, M. (1997). A randomized controlled trial of progressive resistance training in depressed elders. J Gerontol A Biol Sci Med Sci. 52:M27–35. doi: 10.1093/gerona/52A.1.M27
- Singh N, Stavrinos T, Scarbek Y, Galambos G, Liber C, Fiatarone M. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *J Gerontol.* (2005) 60:768–76. doi: 10.1093/gerona/60.6.768
- Blumenthal J, Babyak M, Moore K, Craighead W, Herman S, Khatri P, et al. Effects of exercise training on older patients with major depression. *Arch Internal Med.* (1999) 159:2349–56. doi: 10.1001/archinte.159.19.2349
- Blumenthal J, Babyak M, Doraiswamy P, Watkins L, Hoffman B, Barbour K, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosomatic Med.* (2007) 69:587–96. doi: 10.1097/PSY.0b013e318148c19a
- Carneiro LS, Fonseca AM, Vieira-Coelho MA, Mota MP, Vasconcelos-Raposo J. Effects of structured exercise and pharmacotherapy vs. pharmacotherapy for adults with depressive symptoms: a randomized clinical trial. J Psychiatr Res. (2015) 71:48–55. doi: 10.1016/j.jpsychires.2015.09.007
- de la Cerda P, Cervello E, Cocca A, Viciana, J. Effect of an aerobic training program as complementary therapy in patients with moderate depression. *Percept Mot Skills* (2011) 112:761–9. doi: 10.2466/02.15.PMS.112.3.761-769
- Danielsson L, Papoulias I, Petersson E, Carlsson J, Waern M. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. J Affect Disord. (2014) 168:98–106. doi: 10.1016/j.jad.2014.06.049
- 45. Doose M, Ziegenbein M, Hoos O, Reim D, Stengert W, Hoffer N, et al. Self-selected intensity exercise in the treatment of major depression: a pragmatic RCT. *Int J Psychiatry Clin Pract.* (2017) 19:266–75. doi: 10.3109/13651501.2015
- 46. Hemat-Far A, Shahsavari A, Mousavi SR. Effects of selected aerobic exercises on the depression and concentrations of plasma serotonin in the depressed female students aged 18 to 25. *J Appl Res.* (2012) 12:47–52.
- 47. Ho CWH, Chan SC, Wong JS, Cheung WT, Chung DW, Lau TF. Effect of aerobic exercise training on chinese population with mild to moderate depression in Hong Kong. *Rehabil Res Pract.* (2014) 2014:627376. doi: 10.1155/2014/627376
- Legrand FD, Neff EM. Efficacy of exercise as an adjunct treatment for clinically depressed inpatients during the initial stages of antidepressant pharmacotherapy: An open randomized controlled trial. J Affect Disord. (2016) 191:139–44. doi: 10.1016/j.jad.2015.11.047
- Martinsen EW, Medhus A, Sandvik, L. Effects of aerobic exercise on depression: a controlled study. Br Med J. (1985) 291:109. doi: 10.1136/bmj.291.6488.109
- Mota-Pereira J, Silverio J, Carvalho S, Ribeiro JC, Fonte D, Ramos, J. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. J Psychiatr Res. (2011) 45:1005–11. doi: 10.1016/j.jpsychires.2011.02.005
- 51. Patten CA, Carrie A, Bronars KS, Vickers Douglas V, Ussher MH, Levine JA, et al. Supervised, Vigorous Intensity Exercise Intervention for Depressed

Female Smokers: A Pilot Study. Nicotine Tobacco Res. (2017) 19:77-86. doi: 10.1093/ntr/ntw208

- 52. Siqueira C, Valiengo L, Carvalho A, Santos-Silva P, Missio G, Sousa R, et al. Antidepressant efficacy of adjunctive aerobic activity and associated biomarkers in major depression: A 4-week, randomized, single-blind, controlled clinical trial. *PLoS ONE* (2016) 11:154195. doi: 10.1371/journal.pone.0154195
- Toni G, Murri M, Belvederi S, Zanetidou M, Menchetti G, Ermini F, et al. Physical exercise for late life major depression: the SEEDS study. *Eur J Prevent Cardiol*. (2014) 21 (1 Suppl. 1):S107. doi: 10.1192/bjp.bp.114.150516
- Veale D, Le Fevre K, Pantelis C, de Souza V, Mann A, Sargeant, A. Aerobic exercise in the adjunctive treatment of depression, a randomized controlled trial. J R Soc Med. (1992) 85:541–4.
- 55. Deeks J, Higgins JP. Statistical Algorithms in Review Manager (2007).
- Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* (2010) 1:97–111. doi: 10.1002/jrsm.12
- 57. Cohen J. Statistical Power ANALYSIS for the Behavioral Sciences. Vol. 2 (1988).
- Silveira H, Moraes H, Oliveira N, Coutinho ES, Laks J, Deslandes, A. Physical exercise and clinically depressed patients: a systematic review and meta-analysis. *Neuropsychobiology* (2013) 67:61–8. doi: 10.1159/0003 45160

- Kvam S, Kleppe CL, Nordhus IH, Hovland A. Exercise as a treatment for depression: a meta-analysis. J Affect Disord. (2016) 202:67–86. doi: 10.1016/j.jad.2016.03.063
- Cassilhas RC, Lee KS, Fernandes J, Oliveira MG, Tufik S, Meeusen R, et al. Spatial memory is improved by aerobic and resistance exercise through divergent molecular mechanisms. *Neuroscience* (2012) 202:309–17. doi: 10.1016/j.neuroscience.2011.11.029
- Ruscheweyh R, Willemer C, Kruger K, Duning T, Warnecke T, Sommer J, et al. Physical activity and memory functions, an interventional study. *Neurobiol Aging* (2011) 32:1304–19. doi: 10.1016/j.neurobiolaging.2009.08.001

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Nebiker, Lichtenstein, Minghetti, Zahner, Gerber, Faude and Donath. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.